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Abstract 
 
 
Introduction 
 
A primary risk factor for Primary Open Angle Glaucoma is elevated intraocular pressure 
induced by reduced outflow of aqueous humour through the trabecular meshwork due to 
fibrosis, which causes retinal ganglion cell death and loss of vision. This study aimed to: 1), 
create a rodent model of increased intraocular pressure achieved by the induction of 
trabecular meshwork fibrosis; 2), evaluate the ability of an anti-fibrotic agent, Decorin, to 
diminish established trabecular meshwork fibrosis and lower intraocular pressure; 3), 
correlate these findings to RCG survival and 4), investigate alternative translational methods 
for delivery of Decorin into the anterior chamber. 
 
Methods 
 
Fibrotic agents, kaolin or TGF-β, were intracamerally injected in rats to induce fibrosis and  
intraocular pressure elevation. Following a sustained elevation in intraocular pressure 
human recombinant Decorin was administered intracamerally.   Fibrosis was measured by 
immunohistochemistry and electron microscopy. Retinal ganglion cell counts were 
performed from retinal whole mounts. Visual Evoked Potentials were obtained for functional 
integrity of the visual pathway.   
 
Results 
 
Kaolin injections did not induce fibrosis. TGF-β injections induced fibrosis of the trabecular 
meshwork leading to a sustained elevation in IOP and retinal ganglion cell death, thus 
providing a reliable in vivo model of the ocular fibrosis. Decorin reversed the TGF-β induced 
fibrosis in the trabecular meshwork, lowered intraocular pressure and indirectly prevented 
progressive loss of retinal ganglion cells. Decorin was successfully delivered to the anterior 
chamber in an eye drop formulation.  
 
Conclusion 
 
Decorin may be an effective treatment to reverse fibrosis of the trabecular meshwork, lower 
intraocular pressure and hence prevent RGC death, thereby preserving visual function in 
patients with POAG. 
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Chapter 1 
 
Introduction 
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1.1 Overview  
 
The role of the eye is to facilitate vision and, when compromised through injury or disease, 
blindness can occur. Glaucoma is thought to be a multifactorial, progressive chronic 
neurodegenerative disease leading to retinal ganglion cell (RGC) death and if left untreated, 
results in irreversible blindness. Currently, there is no cure for glaucoma and restorative 
therapies and management of the disease is by controlling intraocular pressure (IOP) 
through eye drops and surgery to slow down the disease process. This introduction will 
guide the reader through ocular anatomy, the risk factors for developing glaucoma and 
current treatment options. Experimental models used to research the pathophysiology of 
glaucoma will also be described. Finally, it is the intention of this chapter to demonstrate 
that fibrosis within eye is a major contributing factor to the development of glaucoma and, 
therefore, being able to model this pathological response experimentally provides 
opportunities to test candidate anti-fibrotic agents, like Decorin, which have shown efficacy 
as potential treatments for other fibrotic conditions.    
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1.2 Functional anatomy of the mammalian visual system   
 
 
“The eye owes its existence to the light. Out of indifferent animal organs the  
light produces an organ to correspond to itself…” – J.W. von Goethe 
 
The eye is a sense organ which allows us to detect and regulate light and its intensity from 
the environment. Light traverses the cornea at the front of the eye through to the retina at 
the back of the eye, where it is converted into an electrical impulse. From here, the electrical 
signal is relayed through the RGC axons which make up the optic nerve to the visual cortex 
located within the occipital lobe of the brain.  
 
The mammalian eye contains two segments, the anterior (to the lens) and posterior (behind 
the lens) segments. The anterior segment is encapsulated by the cornea and is divided into 
two chambers, the anterior and posterior chambers and contains the, iris, ciliary body, pupil, 
zonule fibers and lens (Figure 1.1). Both chambers of the anterior segment are filled with a 
clear fluid known as aqueous humour (AqH).  The cornea is an avascular transparent 
membrane which forms the most anterior portion of the eye. It consists of the epithelium, 
Bowman’s layer, the substantia proporia, Descement’s membrane and endothelium. In 
humans, the cornea is approx. 0.7mm thick in the periphery and 0.5mm at its centre (Snell, 
1998).  The cornea’s primary function is to act as the most powerful refracting surface of the 
eye. It also has a protective role and maintains the integrity of the globe. The iris, attached 
to the anterior surface of the ciliary body, remains suspended in AqH and contains a central 
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aperture, the pupil. The smooth muscle within iris is able to dilate and constrict the pupil to 
alter the level of light entering the eye. The iris is a pigmented diaphragm made up of 
stromal and epithelial cells, approx. 12mm diameter in humans (Snell, 1998) and is located 
between the cornea and the lens.   
 
The junction at which the cornea and iris converge is known as the iridocorneal angle (Figure 
1.1). This anatomical description is used when diagnosing types of glaucoma, based on this 
angle being “open” or “closed”. The angle width alters the ability of AqH to exit the eye and 
therefore has consequences for the pressure within the eye.  AqH is produced in the 
posterior chamber, by the ciliary body, and drains through two outflow pathways from the 
anterior chamber. Of these, the main “conventional” drainage pathway for AqH is through 
the trabecular meshwork (TM) and Schlemm’s Canal (see section 1.2.1).  The other “non-
conventional” pathway permits AqH to passively leave the eye through and around tissues 
including the ciliary muscles, suprachoroidal spaces, sclera and lymphatic vessels. AqH is the 
main determinant of intraocular pressure (IOP).  
 
The transparent, biconvex lens is contained in a capsule basement membrane, epithelium 
and fibres (which continually renew themselves). The lens is held in place by zonule fibers. 
Movement of these zonule fibers permits the lens to focus on near or distant objects and the 
elasticity of the lens permits accommodation of the eye to focus on near objects. As we age 
the elasticity of the lens decreases and it becomes harder to accommodate. The lens also 
becomes densely packed from accumulation of cells (old cells are not removed) and 
sclerosis, resulting in increased opacity and hence, decreased visual acuity.  
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The posterior segment of the eye comprises the vitreous body, the choroid, sclera and retina 
(Figure1.1).  The vitreous body lies between the lens and the retina and is attached to these 
structures from its cortex by suspensory ligaments. The vitreous body is a densely packed gel 
which contains vast amounts of hyaluronic and amino acids, as well as other proteins and 
ascorbic acid. Its scaffold consists of collagen fibrils (mostly type II) and small leucine-rich 
repeat proteins (SLRP) and functions to transmit light whilst helping to maintain the 
structural stability of the eye.  The vitreous gel viscosity decreases with age and becomes 
more liquefied, increasing the chance of vitreal and retinal detachments and other ocular 
pathologies to occur.  Posterior to the vitreous body is the retina (discussed further in 1.2.3) 
which is surrounded by a vascularised lining extending from the optic nerve to the ciliary 
body, known as the choroid. The highly vascularised choroid nourishes the outer layers of 
the retina.. Covering the choroid is the sclera which is a formed from densely packed 
collagenous fibers, encapsulating the outer wall of the eye.  In addition,  the sclera helps to 
regulate IOP (together with the cornea and AqH) by maintaining eye shape. The sclera also 
provides structural support for extra-ocular muscles to attach to the eye.  
 
 
6 
 
 
 
Figure 1.1 Parasagittal section of the mammalian eye. Light passes through the transparent 
cornea at the front of the eye, through the aqueous (AqH) filled chambers and lens across 
the vitreous body to the retina (the light sensing membrane) at the back of the eye. Here 
light is converted by photo-chemical transduction to electrical impulses which are 
transmitted by relay neurons along the optic nerve into the visual cortex for higher cortical 
processing.   
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  1.2.1 Aqueous humour 
AqH is found within the anterior segment of the eye. AqH is constitutively produced and 
secreted from the ciliary epithelium at an average flow rate of 2.75µl/min in humans 
(Brubaker, 1991) and the rat has an average flow rate of 0.35µl/min due to  a much smaller 
anterior chamber volume (15µl)(Mermoud et al., 1996).  AqH functions as a blood/plasma 
substitute for the avascular lens and cornea, to provide nutrients such as ascorbate to 
provide antioxidant protection (Ringvold, 1980), amino acids, neurotransmitters and 
circulation of inflammatory mediators and cells and to remove waste products. AqH also 
contains low levels of growth factors including Transforming Growth Factor-β (TGF-β) for 
immunoregulatory functions of the anterior chamber (Cousins et al., 1991).  Unidirectional 
flow of AqH from the posterior chamber to the anterior chamber is thought to occur due to 
a lower temperature towards the cornea compared to the lens, generating a convective flow 
pattern (Goel et al., 2010). Normally, the rate of AqH production is matched by its drainage, 
which occurs at the  at the iridocorneal angle. In certain disease states, such as glaucoma, 
disruption to the production or outflow of AqH can cause elevations in IOP (Kass et al., 
1980).  From the anterior chamber, the bulk (~90%) of AqH passively leaves the eye through 
the pressure sensitive TM with the remaining AqH leaving through the uveoscleral pathway 
(Gonzalez et al., 2000) (Figure 1.2). 
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Figure 1.2 The formation and flow of aqueous humour in the anterior segment. 
Aqueous humour (AqH) is constitutively produced by the ciliary body. From here it flows uni-
directionally into the anterior chamber where it exits the eye through the trabecular 
meshwork.  
Source: Image adapted from the National Eye Institute, National Institutes of Health 
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  1.2.2 The trabecular meshwork 
The TM is a composition of avascular tissue which bridges across the base of the angle in the 
anterior chamber at the point where the ciliary body and iris insert into the sclera (Figure 1.3 
panel A). The TM comprises of the uveal and corneoscleral meshworks, juxtacanalicular 
connective tissue (JCT) and Schlemm’s Canal (Figure 1.3 panel B). The uveal meshwork 
consists of a very porous net-like structure of endothelial cells and is the outermost layer 
closest to the anterior chamber. Following this, a single layer of endothelial cells is found 
embedded within the corneoscleral meshwork. This layer has a more compact network of 
cellular makeup including trabecular cells, and a meshwork of collagen, elastin and basal 
lamina. Behind this layer is the most densely packed area of the TM, the JCT region, which 
incorporates the inner wall of Schlemm’s Canal and Schlemm’s Canal. Schlemm’s Canal is an 
irregular shaped channel containing an endothelial lined lumen with a discontinuous, thin 
basement membrane. The JCT region in the TM contains an array of endothelial meshworks 
and connective tissue beams covered with contractile trabecular endothelial cells which 
make contact with the basement membrane of Schlemm’s canal.  These cells are embedded 
within extracellular matrix (ECM) which contains various collagens, glycoproteins, elastins, 
fibronectin and laminins (Keller & Acott, 2013). The main function of the TM is to regulate 
the outflow of AqH as it is this area that provides the most resistance and hence determines 
IOP (discussed in section 1.3). Regulation of AqH outflow occurs through relaxation and 
contraction of the ciliary muscle and TM. The TM distends as the ciliary muscle contracts 
resulting in an increase of AqH outflow. Contraction of the TM, through Rho-associated 
pathways (Nakajima et al., 2005), decreases AqH outflow. In addition, the TM cells are 
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capable of phagocytosis and are able to keep the area free of debris, bacteria and other 
particles (Buller et al., 1990). 
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A 
B 
Figure 1.3 The trabecular meshwork.  
(A) shows the location of the trabecular meshwork (TM) in the iridiocorneal angle within the anterior chamber. 
(B) Schematic diagram showing the cellular structure of the TM. The arrows show the direction of aqueous 
humour passage through the TM, across the uveal and corneoscleral meshworks and finally the juxtacanalicular 
connective tissue into Schlemm’s canal where fluid eventually is passed onto the venous drainage systems.  
Source: Image B adapted from Llobet et al., (2003). 
 
1
1
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 1.2.3 The retina, optic nerve and visual pathway 
 
The retina, which is part of the central nervous system (CNS), is the light sensing membrane 
situated at the back of the eye. Retinal cells are continuous with the optic nerve and the 
structure lines eye globe with its most anterior edge conjoined to the epithelial cells of the 
ciliary body and iris.  Within the retina light is converted by phototransduction into an 
electrical signal which is transmitted by the optic nerve to the brain for higher cortical 
processing and image generation.   
 
The retina is highly structured and composed of ten cellular layers that divide outer 
pigmented and inner neural structures (Figure 1.4). Light is absorbed and nutrients for the 
neural retina are metabolised by the outer pigmented layer, commonly known as the retinal 
pigment epithelium (RPE).  Below the RPE lies the neural retina, which comprises (from 
outside in) the photoreceptors (rods and cones), bipolar cells and RGC, along with horizontal 
and amacrine cells. In addition, Müller glia radially span the retina and their processes form 
the external and internal limiting membranes. Light passing through the vitreous traverses 
the retinal layers converging on the photoreceptors. From here light is transduced and 
relayed as an electrical impulse through bipolar interneurons to the RGC. The RGC form both 
single and multiple ganglion cell layers (GCL) depending on their location within the retina 
and synapse with bipolar and amacrine cells. Their axons are non-myelinated within the 
retina and exit the eye at the optic disc where they form the optic nerve. After the RGC 
axons pass through the sclera to leave the eye they become myelinated by oligodendrocytes 
after the lamina cribosa. 
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Figure 1.4 The mammalian retinal layers. Light is transmitted through the retinal layers to 
the photoreceptors. Light energy is transduced into electrical signals which are relayed 
through the retina to the RGC via the bipolar cells and then onto the brain via their axons 
which fasciculate as they leave the back of the eye to form the optic nerve.  
Source: Image modified from Berry et al. (2008) 
 
Once departed from the retina, electrical impulses travel along axons in the optic nerve onto 
the optic chiasm after decussating at the optic tracts, to make their first synapse at the 
lateral geniculate bodies (LGB) or superior colliculus from where they pass the signal onto 
and to the visual cortex (Figure 1.5).  At the level of the optic chiasm, retinal axons from 
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(50% and 95% of axons in humans and rats, respectively) decussate so that they are 
projected through the contra-lateral optic tract. The remaining axons project ipsilaterally. 
Testing, for example, measuring visual evoked potentials (VEP), can be used both clinically 
and experimentally to assess function of the retina and visual pathways.   High IOP damages 
the retina by various mechanisms that causes RGC loss, leading to irreversible blindness as 
seen in, for example, some forms of glaucoma (discussed in section 1.4).  
 
Figure 1.5 The visual pathway. From the retina, electrical impulses travel along axons in the 
optic nerve onto the optic chiasm after decussating at the optic tracts, to make their first 
synapse at the lateral geniculate bodies or superior colliculus, from where they pass the 
signal onto and to the visual cortex.  
Source: Image modified from Haines (2013) 
 
 
15 
 
1.3 Intraocular pressure   
 
 1.3.1 Factors influencing IOP  
Normal IOP for humans ranges between 10-20mmHg (Murgatroyd & Bembridge, 2008) with 
a median of 16-17mmHg (Brubaker, 1998); in the rat the normal IOP can vary depending on 
the species, method of IOP measuring and use of anaesthetics. As previously described the 
main determinant of IOP is balance between the rate of production and outflow of AqH. IOP 
in humans fluctuates throughout a 24 hour cycle (Henkind et al., 1973; Asejczyk-Widlicka & 
Pierscionek, 2007) and studies have suggested that IOP tends to peak mid-morning and 
decrease during the afternoon and evening time (Liu et al., 1998); this is due to the rates of 
AqH production following a circadian rhythm (Reiss et al., 1984). Diurnal variations in IOP 
have also been noted in the rat (Krishna et al., 1995). IOP, under normal physiological 
conditions, will tend to increase slightly with age. Certain factors such as blood pressure 
(Klein et al., 2005), diseased states for example, having Diabetes mellitus (Hennis et al., 
2003), and exercise can alter IOP. Another important factor both clinically and 
experimentally is that use of general anaesthetics e.g. Isoflurane have been demonstrated to 
decrease IOP in humans (Mirakhur et al., 1990) and rodents (Jia et al., 2000).  Certain 
medications for instance the corticosteroid dexamethasone (Weinreb et al., 1985) and anti-
cholinergics (Razeghinejad et al., 2011) may also lead to increases in IOP that can be very 
problematic in patients undergoing ocular surgery. 
 
Other factors such as age, gender, ethnicity may also lead to differences in IOP which, in 
turn, may exacerbate pathological conditions, the most notable disease being glaucoma 
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(discussed further in section 1.4).  The Beaver Dam Eye Study demonstrated a significant 
increase in IOP correlated with increasing age (Klein et al., 1992) and it could be that age 
related biological changes within the eye affect the production and outflow of AqH thereby 
not isolating age itself as a direct factor for determining IOP.  The Barbados Eye Study 
showed that females were more likely to have higher IOP than men. This study also 
indicated that higher body mass index, darker skin and smoking were all correlated with 
higher measurements in IOP (Wu and Leske, 1997). 
 
 1.3.2 Measuring IOP 
 
Clinical and experimental measurements of IOP must provide reproducible and accurate 
readings in order to monitor levels accurately across a certain time period. It is particularly 
useful clinically to evaluate and monitor people at risk of, or with, glaucoma.  The gold 
standard method used clinically and experimentally is tonometry, an indirect and non-
invasive method to obtain IOP (normally expressed in mm of mercury (mmHg)).  Clinically, 
the most reliable IOP measurements are provided using Goldmann Applanation Tonometry 
(GAT) (Bhan et al., 2002). This tonometer can be added to a slit lamp or used as a hand-held 
device and is based on measuring the force applied to applanate the cornea (Murgatroyd et 
al., 2008).  Also used in the clinic and in experimental settings is the TonoPen tonometer, 
which uses the same principle as GAT but requires applanation of a smaller region of the 
cornea. Research has shown this method to be as reliable as GAT (Lester et al., 2001), 
although for IOP measuring in experimental studies using rodents, studies have shown 
rebound tonometry to be more reliable (Kontiloa et al., 2001; Goldblum et al., 2002). The 
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TonoLab Rebound Tonometer is based upon a lightweight probe touching a small area of the 
cornea to measure IOP and is specifically designed for use with rodents. Rebound tonometry 
is widely used in experimental settings and is shown to provide an accurate and sensitive 
reading (Morrison et al., 2009).   
 
1.4 Glaucoma  
  
 1.4.1 Glaucoma definition, epidemiology and risk factors  
 
Glaucoma is a chronic neurodegenerative disease affecting the retina and optic nerve and is 
the second leading cause of blindness worldwide following cataracts (Rieck, 2013). However, 
unlike cataracts, if left untreated glaucoma results in irreversible blindness (Weinreb and 
Khaw, 2004). Currently up to 70 million people have glaucoma worldwide (Williams et al., 
2013), with 8.4 million being permanently blind in both eyes from this disease (Subak-Sharpe 
et al., 2010). Rates of glaucoma are set to increase by 2020 to an expected incidence of 80 
million and, of those, 11 million people will be bilaterally blind from the disease (Quigley & 
Broman, 2006).  Glaucoma, collectively termed the Glaucomas, are a multifactorial and 
heterogeneous group of neurodegenerative diseases. Broadly, they can be acute or chronic 
and are normally classified into i) primary, where there is no known cause; ii) secondary, 
where there is an underlying cause such as injury or infection; or iii) developmental,  which is 
present in infants usually by the age of one. Primary glaucomas can be further classified into 
two main types based on the anterior chamber anatomy, namely from the presence of  an 
“open” or “closed” iridiocorneal angle (see section 1.2). Closed angle glaucoma is normally 
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acute and needs to be surgically dealt with while open angle, where there is still some flow is 
regarded as chronic.  Primary angle-closure glaucoma occurs when the anterior chamber 
angle closes preventing AqH from draining through the TM. People with a narrow anterior 
chamber can develop a pupillary block which is the most common cause of angle closure 
glaucoma. Pupillary block occurs when there is an increased pressure gradient causing the 
iris to move forward and cover the TM. Those from Asian ethnic groups (Seah et al., 1997), 
being of older age (Foster, 2002), having a positive family history or being female (Congdon 
et al., 1992) are more prone to angle-closure glaucoma. 
 
The most prevalent form of glaucoma in the western world is Primary Open Angle Glaucoma 
(POAG) (Kroese & Burton, 2003). In POAG, there is progressive loss of RGC leading to retinal 
nerve fibre layer thinning together with elevated IOP.  Clinically, this can manifest as 
thinning of the neuro-retinal rim at the optic disc (referred to as optic disc cupping), retinal 
degeneration or thinning of the retinal nerve fibre layer on optical coherence tomography 
(OCT) and decreases in vision using visual field or functional testing. Risk factors for 
developing POAG are IOP elevation (Quigley et al., 1980; Sommer et al., 1991), a thinner 
central corneal thickness (Gordon et al., 2002), being of older age (Gordon et al., 2002), 
being of African origin (Gordon et al., 2002) and having a family history of the disease 
(Tielsch et al., 1994) (Figure 1.6).  Gender as a risk factor is still under debate, as some 
studies for POAG prevalence have determined that men were more at risk (Leske et al. 1995; 
Gordon et al., 2002; Rudnicka et al., 2006), whereas other studies suggested that women 
were more at risk (Mitchell et al., 1996) or that there was no gender difference in rates of 
POAG (Klein et al., 1992).   An array of genetic and environmental factors contribute to the 
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onset of glaucoma and many glaucoma associated genes have now been identified. Further 
genetic risk factors are being identified through genome-wide association studies (GWAS) 
showing that mutations in specific genes carry a very high risk of developing POAG (Fingert, 
2011).   GWAS is a robust method to identify common variants in genes from thousands 
people with and without glaucoma. Admixture mapping is another method used for tracking 
genes associated disease progression within certain populations (Mendoza-Reinoso et al., 
2012).  There are many different affected genes associated with glaucoma including the 
Myocilin (MYOC), Optineurin (OPTN) and WDR36 genes.   Mutations in MYOC lead to early 
onset POAG and patients and is believed to lead to TM dysfunction although the exact 
mechanism of this is still debated. Kwon et al., (2009) suggests that protein trafficking and 
mis-folding leads to protein accumulation whereas, Stamer et al., (2011) suggested altered 
exosome release into AqH changes paracrine and autocrine signalling within the TM 
disrupting normal TM homeostasis.  OPTN is not generally associated with increasing IOP but 
is thought to induce premature RGC death by altering pro-apoptotic factors (Morton et al., 
2008). WDR36 is widely expressed throughout the eye and mutations are associated with 
axonal growth in the optic nerve (Chi et al., 2010) and absence of WDR36 from TM cells can 
lead to apoptosis (Gallenberger et al., 2011).  
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Figure 1.6 – Outline of risk factors for elevation in IOP and the development of POAG.  
Glaucoma is a multifactorial disease with those of certain ethnic origins, age, family history 
of glaucoma being more at risk of developing glaucoma. However, the main risk factor is 
increased IOP which leads to damage and death of the retina.  The aetiology of IOP 
elevations are still not completely understood but it is thought that fibrosis within anterior 
chamber could be a factor.   
 
 1.4.2 Pathobiology of POAG 
 
Despite POAG being multifactorial, elevated IOP is a highly significant and, currently, the 
only modifiable risk factor for the development of POAG treated by surgery or 
pharmacologic therapies.  IOP as a risk factor for developing POAG have been extensively 
described in the literature and it is accepted that IOP increases within the eye are caused by 
reductions in AqH outflow (Grant, 1951; Johnson and Kamm, 1983; Tripathi et al., 1994). 
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Grant (1951), using organ perfusion studies, showed reduced outflow of AqH in 
glaucomatous human eyes. Johnson and Kamm (1983) showed that most resistance to 
outflow occurred in the inner wall of Schlemm’s Canal (which can be considered part of the 
JCT region of the TM). Interestingly, in cohorts of patients with high IOP, the patients with 
glaucoma had higher levels of outflow resistance than those without glaucoma (Johnson and 
Kamm, 1983) suggesting there is a pathological process occurring in glaucomatous eyes 
causing outflow resistance.  It has been demonstrated that higher levels of pro-fibrogenic 
cytokines, including TGF-β, are found within the AqH of glaucoma patients and this may lead 
to excess deposition of ECM in the drainage portal (Tripathi et al., 1994) thus changing the 
cellularity of the TM and reducing outflow (discussed further in section 1.5.2).   
 
Studies have shown that lowering IOP helps to preserve visual function in humans with 
POAG (Heijl et al., 2002; Maier et al., 2005) and in experimental rodent models of glaucoma, 
(Morrison et al., 1998) that high levels of IOP can lead to death of RGC. The mechanisms by 
which increases in IOP can lead to RGC death have been under much investigation. Many 
experimental studies have investigated the structural, biochemical and functional changes 
within the retina and ON which lead to RGC death after IOP elevation, and some of those 
when induced experimentally mimic the pathological aspects of the human condition 
(Quigley et al., 2000; Levkovitch-Verbin et al., 2002; Kim et al., 2004; Urcola et al., 2006).  
Nickells (2007) proposed a staged hypothesis for elevated IOP causing changes in glia around 
the optic nerve head, leading to RGC axonal death by compromising the neurotrophic 
support to RGC that in turn causes RGC to undergo apoptosis. Death of RGC may then 
release neurotoxic substances, such as glutamate, which can further damage neighbouring 
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RGC.  Unmyelinated axons arising from the RGC are most vulnerable at the level of the optic 
nerve head and it is this region that is susceptible to damage in glaucoma (Quigley et al., 
1981; Roberts et al., 2010; Dai et al., 2012).  In humans and primates the optic nerve head 
contains  tough connective tissue known as the lamina cribrosa and it has been suggested 
that mechanical forces in this region lead to axonal damage and RGC death (Quigley et al., 
1981).  
 
There is increasing evidence that increases in IOP leads to glaucomatous damage to the optic 
nerve head through damage and loss of astrocytes which, in turn, leads to RGC death 
through the lack of structural and metabolic support from the astrocytes (Dai et al., 2012).  
Death of RGC is permanent and correlates with the degree of blindness. Our understanding 
of the different mechanisms involved in the development of POAG and RGC death, namely 
resistance to AqH outflow through the TM and elevated IOP, provide promising targets for 
therapeutic interventions. Currently though, the only available treatment options for 
patients are based around lowering IOP through surgery or drugs.  
  
 1.4.3 Current treatments for POAG 
 
The aim of treatment for POAG is to reduce IOP and protect the retina and optic nerve from 
further damage. Treatment for POAG can be difficult because patients often present when 
the disease has progressed to an advanced stage, usually when vision is already significantly 
impaired. In the UK, there are now guidelines for screening patients in the community by 
optometrists.  
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The most common, and first line, treatment for glaucoma is the topical administration of IOP 
lowering agents in the form of eye drops (McKee et al., 2004). To date there are no 
medications available to directly protect RGC death although some medications, e.g. 
Brimonidine, have shown some neuroprotective efficacy (Cantor, 2006). Eye drops 
prescribed to patients work by either increasing outflow or decreasing production of AqH. 
They are broadly categorised by their active ingredients and include prostaglandin analogues 
(Tamada et al., 2001) e.g. latanoprost (trading from Pfizer as Xalatan), to increase outflow 
through the uveoscleral pathway by altering pressure gradients and cellular permeability, 
and carbonic anhydrase inhibitors (Lippa et al., 1992) and β-blockers (Johnson et al., 2010), 
e.g. Timolol, to decrease AqH production by the ciliary body.  
 
Eye drops enter the eye through the cornea and conjunctiva, usually by passive diffusion, to 
become mixed in with AqH. The cornea contains both lipids and water in its stroma enclosed 
within a layer of epithelium and endothelium. The presence of lipids and water in the cornea 
makes the delivery of some drugs across this barrier difficult. Many glaucoma drops contain 
preservatives, such as benzalkonium chloride (BAK), to break down tight junctions located 
within the epithelium of the cornea. However, there has been a wave of negative literature 
about the use of BAK in eye drops as it can increase levels of ocular surface disease in 
patients (Becquet et al., 1998; Noecker, 2001; Leung et al., 2008). Newer preservative-free 
drops are now on the market (Rouland et al., 2013).   
 
To date there are no eye drops used to target the main pathology, which is fibrosis of TM, 
(where most resistance to AqH outflow occurs).  Most procedures to increase AqH drainage 
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are carried out through surgical means. There are various laser therapies or surgical options 
to increase AqH drainage. Argon laser trabecularplasty (ALT) is the use of a green 
wavelength laser at 700-100mW delivered at the iridiocorneal angle altering the cellular 
environment in the TM  and inducing changes in trabecular cells to express certain factors, 
such as matrix metalloproteinases (MMP), that remodel the TM reducing resistance to AqH 
outflow (Johnson, 2007). There is some TM cell death using ALT through apoptosis and 
necrosis, but this is balanced by activation of the TM cells that survive (Johnson, 2007).  
However, like all surgery ALT is not without its risks. ALT often starts to fail throughout the 
treatment course in patients.  It is thought that the repeated use of ALT causes cellular 
sheets within the TM to fibrose as a result of excess cellular activation and subsequent 
release of pro-fibrogenic factors that increase resistance of outflow through the TM 
(Alexander & Grierson, 1989).  
 
Glaucoma filtration surgeries, such as trabeculoectomies, are often performed in patients 
when IOP lowering eye drops fail to work.  In a trabeculoectomy the angle is surgically 
opened up so that AqH can drain directly through the sclera, bypassing the TM. One of the 
main complications after this type of surgery is fibrosis of the opening, and this too can 
prevent AqH from leaving the eye (Stahnke et al., 2012).   Drainage implants, composed of a 
silicone tube connected to a drainage plate can also be used to drain AqH from the anterior 
chamber into the sub-tenons space. The implantation of a drainage device causes 
microtrauma to tissue and therefore can lead to scarring from fibroblast activation within 
and around the newly created AqH outflow pathway  (Yoon & Singh, 2004).  
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Experimental studies have been successful in combating post-operative fibrosis of ocular 
tissue using anti-fibrotic agents, and in particular agents that antagonise TGF-β, thereby 
improving the outcome in experimental glaucoma filtration surgery in rabbits (Mead et al., 
2003; Wong et al., 2003; Grisanti et al., 2005) suggesting that reducing fibrosis controls IOP 
and prevents further glaucomatous disease progression.  
 
1.5 Fibrosis in Glaucoma 
  
 1.5.1 Fibrosis 
 
Dysregulated fibrosis is considered by some as an impaired healing response (Mutsaers et 
al., 1997) and is a leading cause of mortality and morbidity in patients (Leask & Abraham, 
2004). Chronic fibrotic disease occurs in many tissues throughout the body, including lung 
(Crouch, 1990), cardiac (Lijen et al., 2000) renal (Liu, 2006) and ocular tissue (Wang et al., 
2009) and is currently very difficult to treat. Of relevance to this project, fibrosis within the 
eye, in particular the TM, is thought to contribute to the pathology occurring in POAG 
(Tamm & Fuschshofer, 2007). These fibrotic conditions all have common pathological 
features including chronic inflammation, the presence of myofibroblasts and excessive 
accumulation of ECM in the microenvironment of affected tissues. Abnormal ECM 
deposition leads to tissue dysfunction, often by perturbing the normal contractility/motility 
of cells.    
 
Following disruption of tissue integrity through infection, chemical insults, ageing or 
accumulation of debris, increased levels of pro-fibrogenic cytokines and growth factors 
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attempt to heal the compromised tissue. However, this healing response is often 
inappropriately perpetuated by an abnormally sustained release of cytokines, including pro-
fibrogenic TGF-βs, resulting in the development of fibrotic lesions and tissue dysfunction.   It 
is widely accepted that TGF-βs are key cytokines that orchestrate acute and chronic fibrotic 
responses (TGF-β will be discussed further in Section 1.6). One of the main cell types in 
stromal tissues responsible for repair and remodelling of the local microenvironment are 
fibroblasts. In the diseased TM, for example, local cells are transformed to a fibroblast 
phenotype and assist in remodelling the compromised tissue.  For example, local epithelial 
cells can be transformed into myofibroblasts, via TGF-β signalling, so that they lose their 
cellular adhesions and become motile and deposit ECM (including collagen, fibronectin and 
laminin) at sites of tissue damage (McAnulty, 2007).  
 
 
 1.5.2 Trabecular meshwork cells and extracellular matrix  
 
TM cells are a heterogeneous group that have secretory, contractile, proliferative, motile 
and phagocytic capabilities and play an important role in TM tissue homeostasis (Polansky et 
al., 1984).   TM cells are key regulators of ECM turnover (Fuchshofer & Tamm, 2009), 
responding to shear and mechanical stresses to regulate AqH outflow by altering local ECM 
deposition/degradation and releasing cytokines that modulate the ECM. The ECM contains 
collagens (the most abundant matrix molecule), fibronectin, laminins and glycoproteins, 
along with various adapter proteins that modulate matrix interactions with cells (Hann et al., 
2001; Ueda et al., 2002) (Figure 1.7). Many types of collagen are found within the TM 
including the fibril-forming (types I, III and V) basement membrane collagen (type IV), 
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filament-forming (type VI) and network-forming collagens (type VIII).  Together these 
collagens provide strength and resilience throughout the meshwork (Weinreb et al., 1996).  
Fibronectin is another major component of the ECM. Fibronectin is a dimeric high molecular 
weight (450kDa) glycoprotein secreted by fibroblasts within the JCT and on the inner wall of 
Schlemm’s canal.  Laminins are heterotrimeric glycoproteins which are present in basement 
membrane and are used to connect basement membrane to other cell layers.  
 
Figure 1.7 Schematic representation of the TM. This image shows the outflow pathway 
through the TM, with particular emphasis on the presence of TM cells embedded with ECM. 
The insert highlights the JCT region cells interspersed and ECM conjugated to the inner wall 
of Schlemm’s canal. 
Source: Image adapted from Acott & Kelley (2008) 
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 1.5.3 Fibrosis in the TM and POAG 
 
There is much evidence that fibrosis within the TM is a contributing factor to the 
pathobiology of POAG by decreasing AqH outflow, causing increased IOP (Tamm and 
Fuchshofer, 2007). The TM is a dynamic structure which is intimately linked to the 
endothelial lined inner wall of Schlemm’s Canal (Figure 1.7) and is anchored to the ciliary 
muscle. Contraction of the ciliary muscles distends the TM, reducing outflow of AqH, 
whereas TM relaxation opens the meshwork and leads to an increase in AqH outflow 
(Weiderholt et al., 2000).  Resistance to outflow through the TM is necessary to maintain the 
IOP and most resistance is supplied by the ECM within JCT region and around Schlemm’s 
Canal (Lütjen-Drecoll, 1999).  Regulated ECM turnover by TM cells also provides resistance to 
AqH outflow by the production of ECM and degrading proteases in response to stress or 
mechanical forces provided by the IOP (Sanka et al., 2007; Acott & Kelley, 2008).  Therefore, 
any alteration in the cellularity or matrix of the TM will alter ECM dynamics and hence the 
resistance that it provides to outflow.  In POAG there is no clear pathological pathway 
leading to raised IOP but there have been studies showing a loss of TM cell function 
(Alvarado et al., 1981; Stamer et al., 1995).  In addition to loss of cell numbers, cells lose 
smooth muscle (actin) cell function in terms of contraction and synthesis. The loss of TM 
cells with age is profound. Human studies have estimated that in youth the eye has in the 
region of 800,000 of these cells, while in a normal 80 year old this will have reduced to 
400,000 (Grierson et al., 1987) but in an 80 year old with open angle glaucoma the numbers 
are far fewer (Alvarado et al., 1984). Due to the active phagocytic and migratory activity of 
TM cells it is possible that their proliferation capacity is limited, hence, the decrease in 
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numbers over a lifetime (Calthorpe & Grierson, 1990). The increase in debris accumulation 
within the anterior chamber may cause more TM cells to detach in order to try and remove 
this. Loss of TM cells will alter the local microenvironment and the levels of ECM. Over time 
the TM cells also alter their phenotype to become less motile and more productive of ECM, 
shown experimentally through decreases in actin and increases in collagen synthesis (Millard 
et al., 1987; Porter et al., 2012).   In addition to alterations in ECM and cell contractility, the 
higher levels of mechanical stress also lead to TM cells releasing various cytokines including 
TGF-β (Liton et al., 2005), which can in turn lead to more ECM deposition through its 
fibrogenic signalling pathways.  
 
1.6 TGF-β  
 
The TGF-βs are a family of growth factors that are important regulators of cellular actions, 
including differentiation, proliferation, migration, cell death, ECM production and modelling, 
immune cell modulation and growth factor production. The response and actions of TGF-β 
are dependent on the cell type and location within the body and, because of this, TGF-β can 
have opposing biological actions depending on context. Three main isoforms of TGF-β exist, 
TGF-β1, TGF-β2 and TGF-β3. Cloning studies have shown that TGF-β1 and 2 are 71% 
identical, yield similar biological activity and are of the same size but contain different amino 
acids at the amino-terminal end (Marquardt et al., 1987).  The TGF-β3 isoform is 78% similar 
to TGF-β2 isoform and its structure is identical to TGF-β2 (Cox, 1995).  Although TGF-β 
expression may be different to that of the TGF-β1 and TGF-β2 isoforms, studies have 
demonstrated that TGF-β3 is often co-expressed with the TGF-β1 and TGF-β2 isoforms (Cox, 
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1995). TGF-β3 is an important growth factor during development, with its expression found 
in high levels within most tissues in the developing embryo (Cox, 1995).   
 
 1.6.1 TGF-β bioactivity 
 
TGF-β bioactivity is tightly regulated by two proteins, a latent TGF-β binding protein (LTBP) 
and a latency associated protein (LAP) that confer latency.  Secretion of TGF-β in a latent 
form enables optimal concentrations of TGF-β to be achieved at the designated site of 
action. The mature latent TGF-β is linked by two disulphide bonds. Dissociation of the 
complex is required for TGF-β to become active and bind to its cognate receptors to initiate 
intracellular signalling (Figure 1.8). Dissociation of the complex to liberate TGF-β in its active 
form can be achieved experimentally through acidic conditions. Biologically, liberation is 
achieved through proteases e.g. elastase (Nathan, 2002) and plasmin (Munger et al., 1997), 
thrombospondins (Crawford et al., 1998), integrins (Annes et al., 2004) and free radicals 
(Barcellos-Hoff & Dix, 1996). Binding of Thrombospondin-1 (TSP-1) leads to a conformational 
change in the LAP, also resulting in release of the active TGF-β cytokine.  Oxidative activation 
can cause to a conformational change in the LAP, releasing the active form of TGF-β (Khalil, 
1999).  
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Figure 1.8 TGF-β bioactivity. The mature TGF-β is in an inactive form which associated to its 
binding proteins (LAP). Binding of TSP-1 dissociates the LAP and releases the active cytokine 
to bind to its cognate receptors.  
 
 1.6.2 TGF-β signalling 
 
Once active, the TGF-β initiates intracellular signalling through interactions with 
transmembrane serine-threonine kinase type 1 and type 2 receptors (Figure 1.9) and 
through the TGFBR3 (betaglycan) co-receptor. TGF-β signalling is dependent on the receptor 
complexes forming.  Betaglycan is able to regulate TGF-β signalling at the receptor level to 
both enhance (Blobe et al., 2001) or down-regulate (Chen et al., 2003) TGF-β signalling.  
Betaglycan is able to regulate TGF-β signalling through its ability to bind the core protein of 
TGF-β and regulate its release to the type 2 receptor.  Binding of TGF-β leads to a 
unidirectional phosphorylation of the type I receptor. This phosphorylation activates the 
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Smad intracellular signalling cascade. Smad2/3, once phosphorylated by the type 1 receptor, 
translocates to form a complex with Smad4 and, from there, relocates as a complex to the 
nucleus. Within the nucleus, Smads and their co-transcriptional factors are able to up- and 
down-regulate gene expression. Although Smads are required for most of TGF-β effects, 
there are other intracellular pathways that are used in conjunction with Smad signalling, for 
example, activation of the MAP kinase pathway (which includes Erk, JKN and the p38 MAP 
kinases) is essential for apoptosis (Chang & Karin, 2001), for epithelial-mesenchymal 
transition (EMT) (Zavadil & Böttinger, 2005) and ECM production (Chiquet et al., 2003). 
Smad-independent signalling also occurs via Rho GTPases (which includes RhoA, Rac1 and 
Cdc42) which lead to cytoskeletal reorganisation permitting cell motility and EMT.  These 
pathways are not exclusive, MAP kinase pathways can lead to Smad activation and thereby 
alter gene transcription. This complex interaction of intracellular kinases across multiple 
pathways demonstrates the plethora of biological actions that TGF-β can have on gene 
expression. 
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Figure 1.9 TGF-β signalling. Binding of active TGF-β to its receptors activates intracellular 
signalling through the Smad, MAP kinase or Rho GTPase pathways to regulate ECM 
production, cell death, cell proliferation and differentiation through gene expression. 
  
 1.6.3 TGF-β and fibrosis 
 
Many experimental and human studies have demonstrated TGF-β as being the most potent 
cytokine to induce tissue fibrosis within the body (Leask & Abraham, 2004). TGF-β activates 
epithelial cells, fibroblasts and macrophages and other cells that contribute to fibrotic 
scarring.  In addition to producing an array pro- and anti-inflammatory mediators from 
various cells, TGF-β can induce its own release from cells. The autocrine ability of TGF-β is 
regulated by expression of its receptors. For example, TGF-β-induced differentiation of 
epithelial cells leads to a down-regulation of TGF-β receptors, thus reducing the downstream 
effects. This autocrine regulation is partly achieved by TGF-β inducing inhibitor proteins (e.g 
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Decorin) that bind and sequester activated TGF-β.  Importantly, TGF-β orchestrates the 
deposition and reduced degradation of ECM by upregulating gene expression of collagens, 
fibronectin and laminins and reducing gene expression of MMP, whilst upregulating MMP 
inhibitors (TIMP), resulting in a net accumulation of ECM and, thereby regulating tissue 
fibrosis. There are different effects on scarring within each of the TGF-β isoforms.  It is well 
known that TGF-β1 and TGF-β2 are associated with increasing fibrosis and scar formation, 
however, TGF-β3 has shown anti-scarring in wound healing models whereby exogenous TGF-
β3 administered to cutaneous wounds reduced scarring compared to controls (Shah et al., 
1995)   
 
 1.6.4 TGF-β in the eye 
TGF-βs are normally found within AqH where it is helps maintain the immune privilege 
within the anterior chamber (Cousins et al., 1991). Although both TGF-β1, TGF-β2 and TGF-
β3 are present, the predominant form normally found within the eye is TGF-β2.  TGF-β2 is 
secreted by ciliary and lens epithelium (Allen et al., 1998), platelets found within the inner 
wall of Schlemm’s Canal (Hamanaka & Bill, 1994) and TM cells. TGF-β is able to induce 
macrophages with immune deviating capabilities and is therefore considered imperative for 
induction of anterior chamber-associated immune deviation (ACAID; Wilbanks et al., 1992).  
ACAID is achieved partly through the immunoregulatory properties of the AqH. Co-culture 
studies have demonstrated that the presence of AqH inhibits proliferation of antigen 
presenting cells and T cells. The first significant immunomodulatory factor in AqH to be 
discovered was TGF-β (Wilbanks et al., 1992). In addition to a direct role of TGF-β from AqH 
inhibiting T cell proliferation (Cousins et al., 1991), Takeuchi et al. (1998) demonstrated the 
35 
 
role of TGF-β in ACAID whereby exogenous TGF-β2 prevented antigen presenting cells 
(macrophages) activating T Cells by lowering levels of IL-12.  TGF-β1 is also found stored 
within the ECM of the TM. Once activated, TGF-β1 and TGF-β2 is released and binds to cell 
surface receptors, some of which are present on TM cells, suggesting an autocrine action. 
Mechanical stress of TM cells induces TGF-β release, providing further evidence of its role in 
TM functioning (Liton et al., 2005; Liton et al., 2009).  In the same way that aberrant levels 
can cause fibrosis in other organs, dysregulated TGF-β signalling has been implicated as a 
major factor for fibrosis of the TM in POAG.  
  
 1.6.5 TGF-β in POAG 
 
TGF-β1 and TGF-β2 have been implicated in the pathogenesis of glaucoma and TGF-β2 in 
particular, has been extensively investigated with regards to TGF-β signalling and 
development of TGF-β induced fibrosis of the TM, in patients with POAG.  The ability of TGF-
β to transform TM cells into myofibroblasts through its actions on α-smooth muscle actin 
has been shown in culture studies (Tamm et al., 1996).  The decrease in TM cell numbers 
observed in patients with POAG is attributed to TGF-β’s inhibitory effects on cell 
proliferation (Borisuth et al., 1992) and its ability to promote phagocytosis (Cao et al., 2003). 
Together with its ability to increase ECM deposition, the data makes TGF-β a prime target for 
investigation into its role in increasing outflow resistance and hence POAG pathobiology.  
 
Enzyme-linked immunosorbent assay (ELISA) of the AqH from patients with POAG reveals 
higher levels of total (i.e. TGF-β bound to LAP) and active (i.e. liberated from LAP) TGF-β2 
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when compared to age-matched controls (Tripathi et al., 1994).  Another study, by Ochiai & 
Ochiai (2000), also using ELISA to determine TGF-β2 levels reported that total TGF-β2 levels 
were similar between POAG patients and controls, and that only the active TGF-β2 levels 
were significantly higher in POAG patients. In addition to higher levels of active TGF-β2 in the 
AqH of POAG patients, these studies and others report negligible active TGF-β1 found in 
AqH, despite both isoforms being potentially able to modulate ECM.  The levels of TGF-β 
isoforms found within AqH can vary depending on the type of glaucoma; for example TGF-β1 
levels increase in neo-vascular glaucoma (Yu et al., 2007) and Pseudoexfoliation glaucoma 
(PXG) (Schloetzer-Schrehardt et al., 2001). In light of the above, TGF-β2 in the anterior 
chamber has been the focus of studying POAG (Tripathi et al., 1994; Ochiai & Ochiai, 2000; 
Ozcan et al., 2004).   
 
One area of particular focus is the effects of TGF-β2 on proteases within the TM, namely, the 
MMP family. Net accumulation of ECM in the TM results from both TGF-β2-induced ECM 
deposition and TGF-β2 induced down regulation of proteases which degrade ECM. TM cells 
express MMP2 and MMP9 enzymes that are secreted in a pro-form, like TGF-β, and need to 
be activated through cleavage by serine proteases including plasmin.  Culture studies have 
shown increases in plasmin inhibition, via PAI-1, that leads to a marked decrease in MMP2 
function (Fuchshofer et al., 2003). This study demonstrated no alteration in MMP2 levels in 
cells after TGF-β treatment but it does highlight that, although TGF-β can induce MMP 
secretion, it may be a failure of MMP activation that contributes to the fibrotic pathology 
seen in POAG. TGF-β is also known to increase expression on TIMPs, thus providing a 
mechanism for further inhibition of MMP (Leivonen et al., 2013).   
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TGF-β1 has similar fibrotic effects to TGF-β2 in cultured TM cells and, although studies 
investigating AqH content of TGF-β isoforms find very little TGF-β1 compared to TGF-β2 
(Jampel et al., 1990), TGF-β1 is found within the TM cells. Gene expression studies have 
demonstrated an increase in ECM proteins and alterations in redox processes within the 
cultured TM cells treated with both TGF-β1 and TGF-β2 (Zhao et al., 2004). Hence, the gene 
profiling in the study by Zhao et al., (2004) suggests that increased levels of TGF-β are 
responsible for changes observed in the TM of patients with POAG. Further evidence for 
TGF-β1 expression by TM cells has been obtained through TM cell culture experiments that 
demonstrate constitutive expression TGF-β1 mRNA and, like TGF-β2, the auto-activation of 
gene expression in an autocrine manner (Li et al., 1996).   
 
Interestingly, TSP-1 is a potent regulator of TGF-β as it dissociates the LAP, liberating the 
active form of TGF-β. TSP-1 is normally found within the JCT region of the TM and its levels 
are increased in POAG, with the hypothesis of higher levels of TSP-1 leading to higher levels 
of TGF-β and hence, more ECM deposition (Khalil, 1999).  A study by Flügel-Koch et al (2004) 
demonstrated higher levels of TGF-β1-induced expression of TSP-1, thereby reinforcing the 
increasing levels of active TGF-β within the TM in glaucomatous eyes compared to normal 
controls.  
 
1.7 Anti-fibrotic agents   
 
Having identified that TM fibrosis is part of the pathology of POAG, it is evident that there 
are still no treatments available to target this aspect of the disease. There are many IOP 
lowering agents available, but they work through other mechanisms, namely by increasing 
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outflow through the uveoscleral pathway or reducing production of AqH (see section 1.4.3).  
Trabeculectomy and laser surgery provide therapeutic efficacy in managing uncontrolled 
POAG but have associated complications as the surgery itself can cause fibrosis, warranting 
further medical intervention.  The use of anti-fibrotic agents, such as mitomycin C, has 
shown to improve surgical success rates (Scott et al., 1998).  Gristanti et al., (2005) showed 
that sub-conjunctival injections of Decorin, a naturally occurring TGF-β inhibitor, was able to 
significantly reduce post-operative scarring in the surgical area and also lower IOP. Another 
study by Mohan et al. (2011) demonstrated that adenoviral gene expression of Decorin 
prevented corneal fibrosis in rabbits providing further evidence for the anti-fibrotic actions 
of the glycoprotein.  
 
Despite there being much investigation into the use of anti-fibrotic agents in ocular surgery, 
they are not currently used in patients with POAG to directly target the TM.  Being able to 
lower IOP through reversing established and/or preventing further fibrosis in the TM would 
provide a promising avenue for more curative treatments. Decorin, through is ability to 
interact with TGF-β and other ECM molecules to inhibit fibrogenesis, as well as having 
immunomodulatory functions, is potentially an effective anti-fibrotic treatment for a 
number of diseases emanating from a fibrotic pathology and hold promise as a new agent to 
treat POAG.  
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1.8 Decorin 
 
 1.8.1 Structure and function 
Decorin is naturally occurring, extracellular leucine rich secreted glycoprotein and is part of 
the chondroitin-dermatan sulphate family of proteoglycans (Figure 1.10).  Human Decorin is 
approx. 70kDa (Brandan et al., 1992), is encoded by the DCN gene on chromosome 12q21.33 
and contains 359 amino acids (Grover et al., 1995). Binding of proteins to the concaved 
shaped Decorin occurs through its 12 leucine-rich repeat core, and its functionality is 
conferred though its associated chondroitin sulphate glycosaminoglycan chains (GAG) 
attached to the cysteine rich N-terminus (Scott et al., 2004).  Decorin was so-called through 
its ability to decorate, or arrange, collagen through its binding of collagen fibrils to its protein 
core. This interaction is required for normal functioning of collagen to provide strength and 
order (Weber et al., 1996). The structure-function relationship between Decorin regulating 
collagen have been confirmed in experiments whereby Decorin null mice presented with 
abnormal collagen fibril formation and weakness in their skin structure (Danielson et al., 
1997).  Decorin can be found in most organs which are rich in collagen such as heart, lung, 
liver and spleen (Hocking et al., 1998). Decorin is also thought to be the primary regulator of 
fibril formation during development of the cornea (Zhang et al., 2009).  Recently, the non-
structural functions of Decorin have become apparent in terms of its immunomodulatory, 
anti-angiogenic, anti-proliferative and anti-fibrotic functions through its ability to bind to 
various growth factors and their receptors.  
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Figure 1.10 Decorin structure and collagen binding.  Decorin has a concave shape, with its 
inner surface for ligand binding.  
Source: Image modified from Weber et al., (1996)   
 
 1.8.2 Decorin and TGF-β  
Decorin’s ability to bind directly to and sequester TGF-β was first demonstrated using 
Chinese hamster ovary cells in a cell proliferation study by Yamaguchi et al. (1990). This 
study followed a similar study that identified Decorin’s ability to attenuate cell proliferation 
(Yamaguchi & Ruoslahti, 1988).   Decorin is able to bind to TGF-β1 and TGF-β2, preventing its 
binding to receptors and subsequent intracellular signalling. However, reports of Decorin 
increasing TGF-β activity in extracted bone matrix have also been noted in the literature 
(Takeuchi et al., 1994).  These contradictory findings may be due to different bioactivity in 
different cells, and/or other ECM protein interactions. Increases in TGF-β production 
generally leads to increases in expression of Decorin (on ECM), which then is able to 
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modulate TGF-β levels in a negative feed-back loop mechanism.  Decorin is also able to 
interact with other ECM molecules through its core protein (Schmidt et al., 1991), e.g. 
fibronectin, and ECM proteases, thus having a direct effect on ECM turnover in conjunction 
with TGF-β signalling. 
 
 1.8.3 Decorin and fibrosis 
 
Fibronectin fibril formation plays a big part in producing thick fibrous strands within the TM 
and contributes to the tensile strength of TM cell necessary when stretching and 
contributing to AqH outflow resistance (Vittal et al., 2005). Decorin modulates MMP activity 
by increasing levels of plasminogen (Davies et al., 2006), favouring higher turnover of ECM 
and leading to ECM degradation. A recent study using Decorin after spinal cord injury in 
rodents demonstrated that Decorin enhanced levels of MMP2 and MMP9 and reduced levels 
of fibronectin and laminin over 21 and 35 days (Ahmed et al., 2013).  Other wound healing 
models in the CNS have demonstrated the use of Decorin to decrease matrix deposition, 
including the deposition of laminin basement membranes and scar formation (Logan et al., 
1999; Davies et al., 2004).   The use of Decorin in disease where fibrosis is a major cause of 
morbidity has been established. For example, Decorin has shown a reduction in fibrosis in 
many pathological conditions including proliferative vitreoretinopathy (Nassar et al., 2011), 
renal fibrosis (Isaka et al., 1996), lung fibrosis (Giri et al., 1997) and juvenile communicating 
hydrocephalus (Botfield et al., 2013). The study by Botfield et al. (2013) used the aluminium 
silicate, kaolin, to replicate the inflammatory response in the subarachnoid space causing 
significant fibrosis, and perturbed CSF drainage, modelling the human condition of 
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hydrocephalus. In this model Decorin attenuated inflammation and fibrosis and prevented 
the development of ventriculomegaly.  The increasing evidence of Decorin as an effective 
anti-fibrotic agent through its actions on TGF-β and its ability to alter ECM turnover provide 
a promising avenue for use to combat the fibrotic pathology seen in POAG. As with other 
pathological conditions investigating the pathobiology and development of new treatments 
require the use of experimental models and, for complete biological effects, the most useful 
modelling comes from in vivo experimentation. 
 
1.9 Modelling POAG in rodents 
 
POAG is a multifactorial disease, therefore modelling the disease experimentally is not 
straightforward. Most rodent models serve to investigate a certain aspect of the disease 
and, not replicating the human condition perfectly, they can be very useful in terms of 
identifying compounds that alter the cardinal features of POAG, which include IOP elevation 
and RGC death.  Rats in particular are suitable for studying POAG as the anterior chamber 
anatomy is very similar, in terms of outflow pathways, to humans (Bouhenni et al., 2012) 
and they are inexpensive and are easily maintained within a laboratory setting.  Mice are 
also often used for their ease of genetic manipulation to create transgenic models. The most 
popular genetic alteration is that of the myocilin gene (MYOC) (Gould et al., 2004). Patients 
with glaucoma have demonstrated higher levels of MYOC expression and this has been 
modelled in mice. Interestingly, point mutations (leading to increased expression) of MYOC 
leads to open angle glaucoma in mice, and dexamethasone and TGF-β increases MYOC 
expression leading to POAG (Tamm et al., 1999; Senatorov et al., 2006).  
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MYOC is also known to associate with ECM proteins and glycoproteins including Decorin 
(Ueda et al., 2002). Similar to rats, mice are inexpensive and easy to maintain. However, 
from a surgical point of view, the mouse eye is a lot smaller than that of a rat making 
intraocular injections more difficult.   Studies using rodent models demonstrate IOP 
elevations and retinal and ON changes similar those shown in POAG patients (reviewed by 
Johnson &Tomarev, 2010). 
Most models of POAG are based around methods to cause IOP elevation, as this is the main 
risk factor for the development of POAG in humans. In rats, the most commonly used 
experimental methods used for IOP elevation include giving intracameral injections of 
viscoelastic substances (Benozzi et al., 2002) or micro-beads to occlude TM drainage 
(Sappington et al., 2010), using lasers to damage cells within the TM (Levkovitch-Verbin et 
al., 2002) and ligation of episcleral vessels (Yu et al., 2006). Although reliable and useful for 
studies to manipulate IOP, these models of IOP elevation are not ideal for investigations of 
TM fibrosis and would not be suitable for testing anti-fibrotic agents such as Decorin. 
However, they are very useful in terms of testing neuroprotective and IOP lowering agents. 
Agents known to cause fibrosis in other experimental models of fibrotic disease e.g. TGF-β 
(Sime et al., 1997), Dexamethasone (Fingert et al., 2001) and kaolin (Botfield et al., 2013) 
may be useful in modelling fibrosis in the TM and hence, be more suitable to assess the 
effectiveness of anti-fibrotic agents.   
 
 
 
 
44 
 
 1.9.1 Intracameral injection of substances to increase IOP 
 
A study by Benozzi et al. (2002) demonstrated that a single injection of hyaluronic acid (a 
viscoelastic substance routinely used during ocular surgery) into the anterior chamber of rats 
led to an increase IOP from a baseline reading of 12mmHg up to 22mmHg, which lasted for 
five days before decreasing towards baseline due to degradation of the hyaluronic acid . This 
study also showed that multiple injections of hyaluronic acid led to significantly higher IOP 
levels over 10 weeks. These effects were followed in another study that showed similar 
results in terms of IOP elevation (Moreno et al., 2005). These hyaluronic-induced IOP 
increases, which are thought to cause direct blocking of the TM outflow pathways, were 
reduced with the application of IOP lowering drops including latanoprost (which increase 
outflow through the uveoscleral pathway).    
 
Sappington et al. (2010) designed a novel method for increasing IOP by intracamerally 
injecting polystyrene microbeads to occlude AqH outflow. This produced a rapid increase in 
IOP which lasted weeks and resulting in a moderate 30% increase in IOP, which is 
comparable to the modest increase seen in patients who develop POAG. This model, 
however, is not suitable for investigating TM fibrosis.   
 
Reproducibility of these models are very favourable and many are useful to assess candidate 
neuroprotective agents as they successfully model RGC death. However, the invasive nature 
and severity from hyaluronate injections on the IOP elevation pose some disadvantages by it 
not being able to cause subtle IOP increases over a period of time. This issue was addressed 
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in the microbead occlusion model that provided the most sustained increases in IOP, 
however, none of these models are useful to assess fibrotic changes within the TM.  
 
 1.9.2 Laser photocoagulation POAG model 
 
Application of a laser beam either directly or indirectly onto the TM causes IOP elevations in 
rats and is one of the main methods used to elevate IOP experimentally (reviewed by 
Johnson &Tomarev, 2010). This method serves to reduce AqH outflow by creating cellular 
disorganisation and deposition of cell debris within the TM.  Levkovitch-Verbin et al. (2002) 
optimised the use of laser in the anterior chamber to create a reliable model of glaucoma in 
rats using translimbal photocoagulation. They demonstrated abnormalities in the TM cellular 
arrangement, scarring within the angle and the presence of red blood cells. They also 
observed complications, including corneal injuries and hyphema (presence of blood) in the 
chronic studies, but these were avoided in their acute models. A previous study which also 
used also lasers directly on the TM showed similar changes in the TM with increased  ECM 
deposition, debris and the presence of macrophages (Ueda et al., 1998).  Here, carbon 
particles from India ink injections accumulated in the TM and, hence, permitted localised 
argon laser treatment.  
 
Despite their complications, laser photocoagulation models are reliable models of creating 
elevations in IOP, and they do mimic cellular changes within the TM which could be useful 
for studies of fibrosis. However, these studies require specialist laser equipment and can 
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damage other ocular structures. Laser ablation may also represent a more severe response 
than that which naturally occurs in patients with POAG. 
  
 1.9.3 Episcleral vein injections and ligation POAG models 
 
In addition to laser photocoagulation, the injection of saline into, or ligation of, the episcleral 
veins is a popular experimental method to reliably elevate IOP in rats (Morrison et al., 1995).  
Injections of saline or ligation lead to sclerosis of the episcleral veins through disruption of 
venous return from the anterior chamber, causing IOP elevations (which can remain high for 
months) and this is correlated with RGC death. Zhong (2013) managed to achieve an 81% 
increases in IOP over 24 weeks, leading to 60% death of RGC using injections of saline into 
the episcleral veins. Yu et al. (2006) demonstrated an elevation in IOP within 24 hours of 
ligation, that lasted for several months. Garcia-Valenzuela et al. (1995) were able to 
demonstrate elevations in IOP following cauterization of two limbal veins, with the highest 
IOP being achieved within the first week. Ligation or cauterization of the episcleral veins can 
reliably elevate IOP and is relatively inexpensive to perform, however, Morrison et al. (2005) 
raised some interesting questions about this model, showing RGC loss from the periphery of 
the retina when most other glaucoma models show preferential loss of RGC proximal to the 
optic nerve head. Another confounding factor with ligation or cauterization is the risk of 
ischemia (Goldblum & Mittag, 2002).  
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 1.9.4  TGF-β gene-transfection model of glaucoma 
 
A recent study by Robertson et al. (2010) demonstrated the effects of TGF-β1 over-
expression in the anterior segment of rat eyes using adenoviral gene transfer.  In these 
experiments raised levels of TGF-β1 led to proliferation of corneal endothelial cell and 
changes in TM actin and ECM accumulation, in addition to ocular hypertension.  A study by 
Shepard et al. (2010) demonstrated similar results, namely elevations in IOP and decreased 
AqH outflow, after adenoviral gene expression of active TGF-β2 in both mouse and rat eyes. 
There was however, a reduction in IOP after 8 days the rat eyes and the authors suspected 
the short-lived transgene expression and rapid IOP decreases may have been due to immune 
responses to the virus. However, there are limited models available to investigate TM 
fibrosis but the research to develop these models is now being found in the literature. The 
most notable study came from Junglas et al., (2012) who were able to successfully 
demonstrate a mouse model of TM fibrosis through up-regulation of the TGF-β signalling 
pathway. 
48 
 
 
1.10 Hypothesis and aims 
  
 1.10.1 Hypotheses 
It is widely accepted that TGF-β levels are increased in AqH of patients with POAG compared 
to patients without POAG, and patients with elevations in IOP are more at risk for 
developing POAG.  IOP elevations are correlated with RGC death in patients and in 
experimental models of glaucoma.  POAG develops due to fibrosis of the TM preventing AqH 
from leaving the eye. The build-up of AqH results in IOP elevations and death of RGC.  TGF-β 
is the main cytokine that orchestrates fibrosis. TGF-β through up-regulation of ECM 
deposition and prevention of degradation, results in ECM accumulation in the TM. In 
addition, TGF-β leads to altered phenotypes of TM cells so that they become phagocytic and 
motile thus decreasing the cellularity of the TM.   
Hence, it is hypothesised that  intracameral TGF-β injections will result in excess ECM 
deposition and reduced ECM degradation at the TM and, as a consequence, IOP will be 
elevated enough to cause RGC death  and;  thatDecorin, through its actions on TGF-β and on 
the ECM, will demonstrate therapeutic efficacy by attenuating established fibrosis and 
reducing elevated IOP and, through its IOP lowering actions, Decorin will promote RGC 
survival.   
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 1.10.2 Aims 
 
1) To develop a reproducible in vivo model of TM fibrosis using fibrotic agents to mimic the 
fibrotic pathology seen in patients with POAG. 
2) To assess the effects Decorin in the developed in vivo model of TM fibrosis and its 
potential as a treatment to attenuate TM fibrosis, raised IOP and RGC loss. 
3) To evaluate novel drug delivery mechanisms for Decorin into the eye for future 
translational studies. 
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Chapter 2 
 
Materials and Methods 
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2.1  In vivo procedures described in Chapters 3-6 
 
 
 2.1.1 Surgery and anaesthetic  
 
After formal training from Professor Martin Berry, all of the surgical procedures used in this 
study were performed by myself at the Biomedical Services Unit at the University of 
Birmingham in accordance with the Home Office guidelines and the 1986 Animal Act (UK). 
The work was performed under a Home Office project license PL30/2720.  Male Sprague 
Dawley rats 175g-200g (Charles River, Kent UK) were used for all in vivo experiments and 
housed with free access to food and water, under a 12hr dark/light cycle. All ocular surgical 
procedures, electrophysiology, optical coherence tomography (OCT) and IOP measurements 
were performed under general anaesthetic using 2-5% Isoflurane/95% O2 (VetTech, 
Cheshire, UK) at a flow rate of 1.5L/min. Local anaesthetic, 0.4% Oxybuprocaine, was used in 
study 1 (Figure 2.1). All intracameral injections of treatment agents were administered 
unilaterally with contralateral eyes as control injections, unless specified.  The initial corneal 
incisions with the 15
o
 blade on 0d induced a very small amount of AqH leakage. The 
subsequent intracameral injections using glass micropipette did not induce any AqH leakage.   
After surgery, rats were administered 0.1mg/kg Buprenorphine (if required) placed in cages 
in a recovery room and monitored by trained animal welfare technicians daily. Rats were 
killed using rising concentrations of CO2 at various time points. The experimental groups, 
treatments, experimental time course and end points in addition to the relevant 
experimental chapters are described in Figure 2.1.  
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Study n Treatment  regime  Control groups Experimental 
Time course 
Endpoint Chapter 
 
Kaolin pilot 
study 
 
8 
eyes 
1.25% Kaolin (n=1)  
3.5% Kaolin (n=1) 
5% Kaolin (n=1) 
10% Kaolin (n=1) 
20% Kaolin (n=1) 
(Injected only  on 0d and 5d) 
 
Intact (n=2 eyes) 
 
PBS (n=1 eye) 
 
0d-21d  
 
 
IOP 
OCT 
IHC 
 
3.2.1 
3.3.1 
 
Kaolin+LPS 
study 
8 
eyes 
Kaolin+LPS (n=4) 
 
(Injected 0d only) 
Kaolin+PBS (n=4) 0d-28d 
 
IOP 
OCT 
IHC 
3.2.2 
3.3.2 
 
Effects of  
anaesthetic 
on IOP 
(Study 1) 
 
6 
eyes 
Isoflurane 
General anaesthetic 
(n=3) 
 
Oxybuprocaine 
eye drop 
anaesthetic 
(n=3) 
 
1 single IOP 
recording 
session per 
week (=3 
sessions over 3 
weeks) 
 
 
IOP 
 
4.2.1 
4.3.1 
 
TGF-β1 dosing 
(Study 2) 
 
6 
eyes 
3.5µl 0.5ng/µl active TGF-β1 
3.5µl 5ng/µl active TGF-β1 
(n=3) 
3.5µl PBS 
(n=3) 
0d-45d 
 
 
IOP 4.2.2 
4.3.2 
TGF-β1 
Latanoprost 
(Study 3) 
 
16 
eyes 
3.5µl 5ng/µl active TGF-β1 
(n=8) 
(Latanoprost drop, n=4) 
(PBS drop, n=4) 
3.5µl PBS 
(n=8) 
(Latanoprost drop, 
n=4) 
(PBS drop, n=4) 
0-45d 
 
(30-45d) 
IOP 4.2.3 
4.3.3 
TGF-β1 
(Study 4) 
18 
eyes 
3.5µl 5ng/µl active TGF-β1 
(n=6) 
3.5µl 5ng/µl active TGF-β1 
then PBS (n=6) 
 
3.5µl PBS (n=6) 
 
 
0d-30d 
IOP 
IHC 
RGC-Death 
 
4.2.4 
4.3.4 
TGF-β2 
(Study 5) 
24 
eyes 
3.5µl 5ng/µl active TGF-β2 
(n=12) 
 
3.5µl PBS (n=12) 
 
0d-30d IOP 
VEP 
EM 
IHC 
RCG-DEATH 
 
4.2.5 
4.3.5 
TGF-β1 
Decorin 
study 
6 
eyes 
3.5µl 5ng/µl active TGF-β1 
then Decorin (n=3) 
 
3.5µl 5ng/µl active 
TGF-β1 then PBS 
(n=6) 
 
0d-30d IOP 
IHC 
RGC-DEATH 
5.2.1 
5.3 
TGF-β2 
Decorin 
study 
12 
eyes 
3.5µl 5ng/µl active TGF-β1 
then Decorin (n=12) 
 
TGF-β2 study 5 
 
0d-30d IOP 
VEP 
EM 
IHC 
RCG-DEATH 
5.2.2 
5.3 
Nanosome 
eye drop 
study 
24 
eyes 
Covalent NS+Decorin (n=4) 
Electrostatic NS+Decorin 
(n=4) 
Intact (n=4) 
NS+PBS (n=4) 
NS only (n=4) 
Decorin only (n=4) 
10 min OCT 
ELISA 
6 
 
Key  
d – day; 
ELISA – Enzyme-linked immunosorbent assay;    LPS – Lipopolysaccharide;                RGC – Retinal ganglion cell                
EM – Electron Microscopy;                                      NS – Nanosome;                                TGF-β – Transforming Growth Factor-β;                       
IHC – Immunohistochemistry;                                 OCT – Optical Coherence Tomography;  
IOP – Intraocular Pressure;                                      PBS – Phosphate Buffered Saline;   VEP – Visual Evoked Potential 
 
 
Figure 2.1 Overview of experimental design. The study, number of eyes (n), treatment, 
controls, duration of experiment, end points and relevant experimental chapters are 
described. 
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 2.1.2 Intracameral Injections of Kaolin 
 
One self-sealing incision was made through the cornea into the anterior chamber using a 15° 
disposable blade (BD Systems, Warwickshire, UK) enabling repeat 3.5µl injections of 1.25%, 
3.5%, 5%, 10% and 20% w/v Kaolin (Sigma, Dorset UK) in phosphate buffered saline (PBS) on 
0d and 5d to determine the optimal concentrations of Kaolin to induce fibrosis (see Figure 
2.1).  
 
  
 2.1.3 Intracameral Injections of TGF-β1, TGF-β2 or Decorin  
 
On 0d, one self-sealing incision was made through the cornea into the anterior chamber 
using a 15° disposable blade enabling repeat 3.5μl injections for 30 days of either PBS (Sigma 
Poole) (PBS0-30d), active TGF-β1 or TGF-β2 (5ng/µl; Peprotech, London, UK) (TGF-β0-30d), TGF-
β (5ng/µl) 0-17d then PBS 21-30d (5mg/ml; Catalent Pharma Solutions, Philadelphia, USA) 
(TGF-β0-17d/PBS21-30d) or TGF-β (5ng/µl) 0-17d then human recombinant Decorin 21-30d 
(5mg/ml; TGF-β0-17d/Decorin21-30d) and using a sterile glass micropipette produced in-house 
from a glass capillary rod (Harvard, Kent UK) (see Figure 2.2). An injection regime of TGF-β 
from 0-17d was determined from the IOP data gathered in the initial TGF-β 0-30d 
experiments. By 17d the IOP had increased and was maintained at a higher level compared 
to controls, therefore 21d was considered a suitable time point to inject Decorin/PBS 
treatments. No injections were given between 18-20d to ensure IOP remained at raised 
levels by 21d after cessation of TGF-β injections at 17d.  
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Figure 2.2 Intracameral injections. (A) Intracameral injection using a disposable 15
o
 blade. 
The two-step incision is made through the cornea to promote a self-sealing wound suitable 
for repeat injections. (B) Intracameral injection of agents using a glass micropipette.   
 
 2.1.4 TGF-β model validation using latanoprost eye drops  
 
Latanoprost (trading under Xalatan™ Pfizer) eye drops (VetTech, Cheshire, UK) were 
administered to assess its IOP lowering abilities in the TGF-β model of elevated IOP. Studies 
with Latanoprost were conducted as part of the TGF-β model development (Figure 2.1 study 
3). Administration of latanoprost would be used to assess if the TGF-β model is able to 
respond with a well-known IOP lowering agent and validate the IOP increases observed in 
the TGF-β1 group.   Latanoprost or control PBS drops were administered once a sustained 
elevation in IOP had occurred by 30d until the end of the experiment at 45d.  
A B 
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 2.1.5  In vivo nanosome procedures described in Chapter 6 
 
This study investigated the use of an oligioarginine cell penetrating peptide nanosome as a 
potential drug delivery system into the eye. All peptide synthesis was performed by Dr 
Felicity de Cogan and in vivo testing carried out by myself.  Briefly, nanosome peptide 
sequence were synthesised using standard Fmoc solid phase support synthesis methods. To 
form the electrostatic drop, nanosome peptides and Decorin were mixed at a 1:1 (v/v) and 
incubated for 5 min. Covalent Decorin/nanosome drops were synthesised using a maleimide 
linker to crosslink the amine group of the nanosome with a thiol group on the Decorin 
protein sequence. An Fmoc Ahx linker was added to allow effective addition of a 5/6-
carboxyfluorescein label to fluorescently label the nanosome. 
 
Electrostatic, covalent or control Decorin and PBS drops were placed bilaterally onto the 
cornea in awake, manually restrained, rats and left for 10 min when rats were killed using 
increasing concentrations of CO2. Following death, 10-20µl of AqH was removed and stored 
at 4
o
C ready for analysis of Decorin levels by ELISA (Figure 2.1).  A patent has been filed 
relating to the nanaosome preparations (UK Patent Application Number 1401453.4). 
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2.2 Rebound Tonometry  
 
  
 2.2.1 Principles of Rebound Tonometry 
 
The measurement of IOP is essential to monitor the progression of glaucoma in patients and 
for this project IOP was one of the main outcomes to assess the validity of the acute and 
chronic model of raised IOP.  There are different types of tonometers available for use 
clinically and experimentally, most of which are calibrated for millimetres of mercury 
(mmHg).  For human (in particular children and uncooperative patients) and animal 
experiments, rebound tonometers are ideal (Moreno-Montañes et al., 2011) and widely 
used to provide non-invasive intraocular pressure measurements in animals.  The TonoLab™ 
(ICare, Helsinki, Finland) is a tonometer specifically designed for rodents and its accuracy and 
reliability for measuring IOP has been demonstrated in previous studies (Pease et al. 2011). 
The hand-held, calibrated, device relies on a looped coil wrapped around a metallic core, 
creating a force to propel the 1.8mm diameter plastic ended steel probe against the cornea. 
The probe (which is held in place by an electromagnetic field) deceleration is measured and 
used to calculate IOP in mmHg and the speed of deceleration is inversely proportionate with 
IOP.    
  
 2.2.2 Protocol for Rebound Tonometry 
 
Monitoring of IOP using the Tonolab rebound tonometer was carried out at intervals for the 
duration of the experiment, to provide reliable and reproducible readings to ascertain if 
there are any pressure differences between treatments.  All IOPs were recorded between 9-
11am to avoid the diurnal variations (which also occur in both humans and rodents; Moore 
57 
 
et al., 1996). The TonoLab was placed at a 90
o 
angle against the central part of the cornea (to 
reduce IOP measurement variability of corneal thickness) of anaesthetised rats (Figure 2.3) 
and 6 rebound measurements are taken to give an average IOP measurement in mmHg 
(calibrated by the device). For all graphical data points described in the experimental 
chapters, 3 readings (of 6 rebounds each) were taken and averaged to ensure a reproducible 
measurement (Tsuruga et al., 2012).  Since anaesthetic is known to lower IOP (Jia et al., 
2012) all anaesthetic exposure times were constant for all IOP readings avoid confounding 
IOP measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3  Rebound tonometry. Rats were anaesthetised and placed flat on the surgical 
table. The tonometer (the black hand-held machine to the left of the image) was placed 
horizontally towards the centre of the cornea and held in place for IOP readings to be taken 
(A). Size of the probe used in the Tonolab tonometer (B).  
 
A B 
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2.3 Functional assessment using VEP for experiments described in chapters 4-5 
 
  
 2.3.1 Principles of visual evoked potential recordings 
 
The visual evoked potential (VEP) is a quantitative electrophysiological assessment that is 
used clinically to detect and monitor glaucomatous damage to the visual pathway and 
experimentally to assess and monitor neuroprotective compounds in vivo. It measures the 
functional integrity of RGC and the optic projections through the optic chiasm and optic 
tracts, through the LGN to the visual cortex. Different stimuli allow assessment of different 
aspects of visual function. Flash VEP are recorded after a flash of light to the eye and which 
is measured by electrodes placed over the occipital cortex and the latency and intensity of 
particular aspects of the recorded waveform are assessed (e.g. shown in Figure 2.4). 
Previous studies have shown reduced VEP amplitude to correlate with axonal loss after 6 
days in a rat model of optic neuritis (You et al., 2011) and VEP is used clinically to assess 
optic nerve function (Holder, 2004).  Studies in optic neuritis (You et al., 2011) have 
demonstrated evidence to suggest that amplitude on VEP reflects the number of functional 
optic nerve fibers and, in these models, latency reflects the state of myelination. Similar 
studies show that decreases in amplitude on VEP correlates with decreasing RGC numbers 
being able to transmit signals to the brain (Heiduschka, et al., 2010). Nomenclature for VEP 
are based on peaks, for example, P1 representing the first peak, and negative deflections, for 
example, N1 representing the first negative deflection (Figure 2.4). Reductions of amplitude 
have previously been reported at N1-P1, P1-N2, and N2-P2 (Zhang et al., 2013) and was 
measured in the studies presented in Chapter 4.  
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Figure 2.4 VEP trace with selected parameters. Amplitude and latency will be analysed from 
P1 to N2. 
  
 2.3.2 Protocol for visual evoked potential recordings 
 
Five days prior to VEP recordings stainless steel screws were implanted at 7mm posterior to 
begma, 3mm lateral to the midline at a depth of 0.5mm into the skull to connect the positive 
recording electrodes. The reference (negative) skull screw electrode was placed on the 
midline, 3mm anterior to bregma. The skin was sutured around the screws. For VEP 
recordings on experimental day 30, rats were dark-adapted overnight and VEP recordings 
were carried out using HMsERG (Ocuscience) in a light sealed room with preparation under 
dim red light. Rats were anaesthetised using 2% Isoflurane for the duration of recordings and 
readings were taken in a 37
o
C temperature controlled Faraday cage to reduce electrical 
interference (kindly made and supplied by Maj Richard Blanch, Molecular Neuroscience 
Group).  A needle ground electrode was placed in the midline dorsal subcutaneous tissue at 
the base of the tail. Electrode impedance was measured and kept below 2k Ω. A mini-
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Ganzfeld stimulator was used with increasing stimulus intensities of 300, 3000 and 
25,000mcd/s/m2, which were averaged 100 times at each intensity with a recording 
duration of 250ms and an inter-stimulus interval of 1s. VEP from each eye were recorded 
separately by uniocular occlusion.  The amplitude of VEP was measured from the first peak 
(P1) to the second negative peak (N2) in ERGView (Ocuscience) by an observer blinded to 
the identity of the treatment groups. 
 
2.4 Ocular imaging using Optical Coherence Tomography for experiments described in 
chapters 3 and 6 
 
  
 2.4.1  Principles of Optical Coherence Tomography  
Optical Coherence Tomography (OCT) is an imaging technology used routinely in clinical and 
experimental settings to analyse various ocular structures.  OCT functions by using a near 
infra-red light to construct a high resolution cross sectional image of the retina and/or 
anterior segment of the eye (cornea and iridiocorneal angle). It is similar to ultrasound, 
whereby it collates distance from the time delays of reflected signals, however, unlike using 
sound it uses optical waves to produce cross sectional imaging of the retina.  
 
 2.4.2 OCT Protocol  
 
Anterior chamber imaging was conducted using a Heidelberg SPECTRALIS Spectral Domain 
Optical Coherence Tomography (SD-OCT) with the SPECTRALIS Anterior segment Module 
(Heidelberg Engineering, Heidelberg, Germany). Rats were anaesthetised with 2-2.5% 
Isoflurane and placed on the imaging stage. Multiple images of the anterior segment were 
taken manually for qualitative analysis.  
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2.5 Retrograde labelling of RGC and retinal wholemount preparation  
 
 
Optic nerves were injected with 2µl of a 4% solution of FluoroGold (FG-hydroxystilbamidine) 
retrograde tracer (Cambridge Bioscience, Cambridge UK), 2mm from the lamina cribosa. This 
is a reliable and validated method for labelling RGC (Dong et al., 1996; Chui et al., 2008),  
widely used to identify and quantify RGC by immunofluorescence (FG fluoresces under blue 
excitation of 300-400nm). FG diffuses into axons and is retrogradely transported by 
lysosomal transport (Wessendorf, 1991) RGC somata.  Rats were killed 48h after FG 
injections using increasing concentrations of CO2.  The cornea, iris, lens and vitreous were 
removed and the retina and associated sclera were fixed in 4% paraformaldehyde (PFA, 
Sigma, Poole) in PBS for 2 hours fixation at room temperature. After 2hr, the retina placed 
on a glass slide, flattened after radial incisions divided the retina into quadrants (Figure 2.5) 
and mounted with Vectamount media (Vector Labs, Peterborough, UK) and stored at 4
o
c 
before immunofluorescence imaging (see section 2.9).  
 
 
 
 
 
 
 
 
 
Figure 2.5 Retinal wholemount preparation. The retina is flattened after radial incisions 
divided the retina into quadrants for immunohistochemical analysis.  
Source: Image modified from Vidal-Sanz et al. (1991) 
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2.6  Tissue processing for immunohistochemical analysis  
 
Animals were killed using increasing concentrations of CO2 and perfused using 4% 
paraformaldehyde (PFA) in PBS.  Eyes were post fixed by immersion with PFA 4% for 2 hours 
at 4
o
C before cryoprotection. The eyes were cryoprotected by sequential immersion in 10%, 
20%, 30% sucrose in PBS at 4
o
C for 24 hours each before embedding in optimal cutting 
temperature (OCT) embedding medium (Thermo Shandon, Runcorn, UK) in peel-away mould 
containers (Agar Scientific, Essex, UK). The tissue embedded in OCT was rapidly frozen in 
crushed dry ice and stored at -80°C. Eyes were allocated a block number to blind the user of 
from treatment or control groups and sectioned in the para-sagittal plane at -22°C using a 
Bright cryostat microtome (Bright, Huntingdon, UK) at a thickness of 20µm, mounted on 
positively charged glass slides (Superfrost plus; Fisher Scientific, Pittsburgh, USA) and stored 
at -20
o
C until use.   
 
2.7 Immunohistochemistry 
 
 2.7.1 Principles of Immunohistochemistry 
Immunohistochemistry is a technique to identify proteins and their localisation within tissue 
using antibodies to bind their specific antigens on the protein of interest. These studies used 
the indirect immunofluorescent method (Figure 2.6) and the avidin-biotin complex (ABC) 
method (Figure 2.7). For indirect immunofluorescent labelling tissue samples are were 
incubated with a primary antibody which binds to the antigen of interest and then the 
primary antibody is bound by a fluorescently tagged secondary antibody (raised in the same 
species as the primary antibody). Multiple secondary antibodies can bind to the primary 
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antibody providing signal amplification which is detected using an epi-fluorescent 
microscope.  The fluorescently labelled secondary antibody absorbs and emits light at 
specific wavelengths which can then be detected by the fluorescent microscope.  In the ABC 
method of immunostaining, biotin that is conjugated to the secondary antibody binds to the 
preformed ABC complex. ABC is already bound to HRP catalyses oxidation of added DAB 
yielding brown staining of the primary antibody binding site. ABC immuostaining is visualised 
under a light microscope.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2.6 Indirect immunofluorescence. The antigen of interest is bound by a primary 
antibody. The primary antibody is bound by a secondary antibody which is conjugated to a 
fluorescent dye. The light emission from the fluorescent dye can be detected with a 
fluorescent microscope.  
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Figure 2.7 ABC method of immunohistochemistry. The antigen of interest is bound by a 
primary antibody. The primary antibody is bound by a biotinylated secondary antibody 
which binds to preformed ABC complex. HRP within the ABC complex, reacts with added 
DAB yielding a brown coloured stain where the primary antibody bound to the antigen of 
interest.  
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 2.7.2 Protocol for immunofluorescence staining  
 
 
Thawed frozen sections were washed 2 X 3 min and permeabilised with PBS containing 0.1% 
Triton x-100 (PBS-T; Sigma, Poole UK). In order to keep reagents localised over the tissue, a 
hydrophobic barrier was placed around each section using an ImmEdge™ pen (Vector 
Laboratories).  Slides were blocked for 30 min in 0.5% bovine serum albumin (BSA; Sigma, 
Poole, UK) and 15% normal goat serum (Vector Laboratories) in PBS-T. BSA prevented non-
specific binding of the primary and secondary antibodies. However, goat serum was also 
used as an additional blocking step to prevent non-specific binding of the secondary 
antibody specific to the species it was raised in. Tissue sections were incubated with primary 
antibody (Figure 2.8) for either 1hr at room temperature or 24 hr at 4
o
C in a humidified 
chamber before being washed 3x5 min. Sections were then incubated for 1hr with 
secondary antibody at room temperature. After incubation, the excess secondary antibody 
(Figure 2.8) was removed by 3x5min washes with PBS-T. Finally, slides were mounted in 
Vectorshield mounting medium containing the nuclear marker, DAPI (Vector Laboratories), 
and stored in a light-proof container at 4°C. Incubation of tissue sections with secondary 
antibody alone were used for reagent controls.  
  
 2.7.3 Protocol for immunoperoxidase 
Thawed frozen sections were washed 2 X 3 min in distilled water and incubated for 30 min in 
0.3% H202 in 70% methanol (diluted in PBS) and after, were washed 2 X 3 min in PBST. In 
order to keep reagents localised over the tissue, a hydrophobic barrier was placed around 
each section using an ImmEdge™ pen.  Slides were blocked for 30 min in 0.5% bovine serum 
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albumin (BSA; Sigma, Poole, UK) and 15% normal serum (Vector Laboratories) in PBS-T. 
Tissue sections were incubated with primary antibody (Figure 2.8) for 24hr at 4
o
C in a 
humidified chamber before being washed 3x5min in PBST. Sections were then incubated for 
30min with the biotonylated secondary antibody at room temperature. After incubation, 
sections were washed 3x5 min in PBS-T and incubated for a further 30 mins in the ABC 
complex. Sections were washed in PBST, 3x5 min, and diaminobenzidine (DAB; Vector 
Laboratories) substrate was added. Finally, slides were mounted in Vectorshield mounting 
medium (Vector Laboratories) ready for analysis using the light microscope.  
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Figure 2.8 Antibodies used for immunostaining. 
 
Antibody Species Dilution Marker For  Supplier Catalogue 
Number 
TGF-β1 Rabbit 1/200  TGF-β1  Santa Cruz 
Biotechnology, 
Texas, Usa 
 
Sc-146 
Laminin Rabbit 1/200 Laminin  Sigma-Aldrich, 
Dorset, Uk 
L9393 
Fibronectin Rabbit 1/200 ECM Sigma-Aldrich, 
Poole, UK 
F3648 
ED1(Cd68) Mouse 1/400 Macrophages Serotec, Oxford, 
Uk 
Mca341r 
ΒIII-Tubulin 
 
 
Mouse  
 
1/400 Neuronal 
marker  
Sigma-Aldrich, 
Poole, UK 
T8660 
Decorin Mouse  
 
1/400 Human Decorin Abcam, 
Cambridge, UK 
Ab54728 
 
MMP2 
 
Rabbit 
 
1/100 
 
MMP2 
Abcam, 
Cambridge, UK 
 
Ab37150 
 
MMP9 
 
Rabbit 
 
1/100 
 
MMP9 
 
Merck Millipore, 
USA 
 
Ab804 
 
TIMP2 
 
Rabbit 
 
1/100 
 
TIMP2 
 
Santa Cruz, USA 
 
SC-5539 
Biotinylated 
Anti-Rabbit 
IgG 
Goat 1/1000 Rabbit IgG Vector 
Laboratories. 
Peterborough, UK 
BA1000 
Alexa Fluor 
594 
Goat 1/500  
 
Rabbit IgG Life Technologies, 
Paisley, Uk 
A11037 
Alexa Fluor 
488 
Goat  
 
1/500 Mouse IgG Life Technologies, 
Paisley, Uk 
A11029 
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2.8 Image analysis and quantification  
 
 2.8.1 Semi-quantitative image analysis for TM fibrosis  
 
After immunofluorescence staining, sections were viewed on a Zeiss Axioplan 2 epi-
fluorescent microscope (Zeiss, Germany) and images captured using a Zeiss AxioCam HRc. 
Images were quantified using the Java based Image J software (National Institutes of Health). 
For evaluation of immunofluorescence staining, region of interest of the same set size for all 
eyes/treatments were selected to make sample counts within the TM and the percentage of 
immunofluorescent pixels above a set background threshold were calculated using ImageJ 
software. The levels of brightness were altered to include all stained areas of the TM on 
intact eye sections to determine the threshold level for test group analysis. Images were 
then saved as randomised numbers to ensure treatment groups were anonymised for 
quantification. These methods to quantify immunofluorescence staining have been used 
previously (Botfield et al., 2013). 
 2.8.2 RGC survival 
FG-filled RGC were counted under a Zeiss fluorescence microscope with an UV filter 
(365/420 nm) at x20 magnification and photographed using an Axiocam HRc camera coupled 
to Axiovision software (Zeiss Ltd, Hertfordshire, UK).  Images were captured from 3 different 
areas of each quadrant (Figure 2.9) and images assigned a random number to blind the 
counter from treatment groups. RGC counts expressed as RGC/mm
2
±SEM (Ahmed et al., 
2011) performed using ImagePro (Media Cybernetics, MD, USA). 
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Figure 2.9 RGC counting. Red squares show the areas in which RGC were actually counted. In 
each retina 3 different areas of 0.6mm x 0.5mm from each quadrant were imaged and 
counted using Zeiss Axiovision software.  
Source: Image modified from Vidal-Sanz et al. (1991) 
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2.9 Enzyme-linked immunosorbent assay 
 
 2.9.1 Principles of enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) is a biochemical assay quantifying protein 
levels by detection of antigens using antibodies. Samples in solution are placed into a 96 well 
plate previously coated with antibodies to capture the antigens of interest.  An additional 
detection antibody (biotinylated) is added to bind to the same antigen in the sample (using a 
different epitope to the capture antibody). Hence, the antigen of interest is sandwiched 
between the capture and detection antibodies. HRP-Conjugated Streptavidin binds the 
detection antibody. The addition of a substrate permits oxidation of HRP and yields a 
colourmetric change detectable and quantified using a microplate reader of optical density, 
which is positively correlated with the antigen concentration in the sample (Figure 2.10). 
Optical density for known (standard) concentrations of antigen is then used to determine 
the sample concentration.  
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Figure 2.10 ELISA assay steps 
 
The sample is added to wells coated with capture antibody. A biotinylated antibody is then 
used to detect the antigen.  The HRP conjugated with Streptavidin binds to the detection 
antibody and the addition of a substrate oxidises HRP creating a coloured product.  
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 2.9.2 Protocol for Decorin ELISA of Aqueous humour samples 
 
ELISA was used to detect levels of Decorin in AqH. All ELISA experimental protocols were 
performed using the R&D Systems human Decorin DuoSet ELISA kit (Catalogue DY143, R&D 
systems, Abingdon UK). All reagents were supplied in the kit.  
 
Mono-clonal mouse anti-human Decorin capture antibody (2µg/ml) was added to both 
standards and sample allocated wells on a 96 well plate and was incubated overnight at 
room temperature. Wells were washed in PBS containing 0.05% Tween®20 (pH7.2-7.4) 
before placing in blocking solution of 1% BSA in PBS (pH7.2-7.4), to block non-specific 
binding, for 1hr at room temperature. Wells were washed again and human Decorin 
standards (serial dilutions up to 2000pg/ml; supplied by R&D) and aqueous humour samples 
(1/2 dilutions) in duplicate were incubated for 2hr at room temperature, then washed and 
incubated in biotinylated mouse anti-human Decorin detection antibody (250ng/ml) for 2 hr 
before being washed again. Streptavidin-HRP (1/200 dilution) was then added to each well 
and incubated for 20 min at room temperature and kept away from direct light. After further 
washing wells were incubated in 1:1 H202 and tetramethylbenzidine substrate solution in the 
dark. After 20 minutes the 2N H2SO4 stop-solution was added and the optical density was 
read on a microplate reader at 450nm. Blank values subtracted from all readings. 
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2.10 Transmission Electron Microscopy of the TM 
  
 2.10.1 Principles of Transmission Electron Microscopy 
Electron microscopy visualises cellular ultrastructure using electron beams to acheive 
resolution (e.g. x200,000) of cellular ultrastructure. The electron source emits electrons 
through a vacuum column which focus on the specimen through an electromagnectic lens, 
through the specimen onto a fluorescent screen (visualised by the user).  
 2.10.2 Tissue processing and sectioning for Transmission Electron Microscopy 
Eyes were fixed in 4% glutaraldehyde in 0.1M phosphate buffer (TAAB, Berks UK) for 48 
hours, bisected in the sagittal plane and 3 radial sections of tissue including cornea, TM and 
ciliary body were isolated from one half globe for embedding using Vanna’s scissors. The 
remaining half globe was stored in glutaraldehyde.  Tissue was washed in 0.1M Phosphate 
buffer pH 7.0 for 30min and fixed in 1% Osmium (ElectronMicroscope Sciences, Hatfield) for 
45 min at room temperature, then tissues washed 3x in 0.1M Phosphate Buffer and 
dehydrated through increasing concentrations of ethanol from 50%-100% diluted in distilled 
water for 10 min at each concentration. Tissue was then placed in pure propylene oxide to 
remove ethanol residue for 2x10 min and immersed in resin for 24hr (Electron Microscope 
Sciences, Hatfield UK) at room temperature.  Resin blocks were labelled with eye number 
and incubated at 56
O
C for 24hr before being stored at room temperature.  For analysis 
under the TEM, resin blocks were trimmed and semi-thin (1um thick) sections cut using a 
glass knife and stained with 1% toluidine blue (Agar Scientific) in 1% sodium borate (Fischer 
Scientific) by heating over a paraffin flame for up to a minute before rinsing in distilled 
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water. The sections were then viewed under a light microscope to identify the area of 
interest (the TM).  
With technical assistance from, ultra-thin sections, using a diamond knife, were cut by 
Theresa Morris (EM technician, Centre for EM, University of Birmingham). Once the resin 
block face was cut down to approx. 0.5-0.75mm
2 
a diamond knife was used to cut gold (80-
90nm) sections and placed on a Formvar-coated copper mesh grid (Agar Scientific). Grids 
were stained with uranyl acetate for 5 min, rinsed in deionised water x 3 and placed on filter 
paper to dry before staining with Lead citrate for 8 min and washing in deionized water x 3 
and stored at RT in a grid box for later TEM.   
 2.11 Statistics 
 
All statistical analyses were performed using SPSS 20 (IBM, USA) with assistance from Dr. 
Peter Nightingale, Statistician at University Hospital Birmingham. Normal distribution tests 
were carried out to determine the most appropriate statistical analysis to use to compare 
treatments. Statistical significance was determined as p<0.05. The NC3Rs resource equation 
was used to determine a suitable number of animals for experiments.  The resource 
equation is used to determine sampling sizes in a hypothesis driven experiment and usually 
requires smaller sampling sizes to ascertain differences between treatments compared to 
power calculations, which are generally required to estimate parameters of treatments.  IOP 
data were measured using the within-subjects repeated measured design or generalised 
estimated equations. TM fibrosis, RGC survival and ELISA data were tested for significance 
using Student t test or 1-way ANOVA for >2 group comparisons ±SEM.  VEP data were 
analysed using the Generalised Estimated Equations (autoregressive correlation matrix). 
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Chapter 3 
 
Modelling Trabecular Meshwork 
Fibrosis using Kaolin/LPS 
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3.1 Rationale 
 
 
The aim of this pilot study was to assess the efficacy of two well-known pro-inflammatory 
and fibrogenic agents, lipopolysaccharide (LPS) and kaolin, to cause fibrosis in the trabecular 
meshwork (TM) and sustained IOP elevations after injections into the anterior chamber of 
the rat eye. If successful, these models could be used to investigate candidate anti-fibrotic 
agents to combat these pathological aspects of glaucoma.  Intracameral injections of LPS, a 
potent bacterial wall endotoxin, has been used to model the ocular inflammatory disorder, 
uveitis in rats, by inducing macrophage infiltration into the anterior segment of the eye 
(Sakimoto et al., 2009). Macrophages release pro-inflammatory cytokines which transform 
local trabecular cells into fibroblasts causing fibrosis.  Basal cistern injections of kaolin, an 
aluminium silicate, increases endogenous levels of TGF-β from meningeal fibroblasts and 
macrophages leading to tissue fibrosis in the sub-arachnoid space blocking CSF drainage 
portals and inducing ventriculomegaly (Botfield et al., 2013).  Fibrosis of the TM seen in 
POAG probably arises, in part, from abnormally high levels of TGF-β in the aqueous humour 
(AqH) acting on cells within the TM (Tamm et al., 2007).   
 
Based on the observation that LPS induces macrophage infiltration and pro-inflammatory 
cytokine release together with the fibrogenic properties of kaolin, it was hypothesised that 
intracameral injections both of LPS and kaolin would lead to a sustained elevation in IOP 
through restriction of AqH outflow from TM fibrosis.  
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To test this hypothesis, a pilot study was designed to; (1) determine optimal concentration 
of kaolin to inject into anterior chamber to achieve maximal TM fibrosis; (2) intracamerally 
injected kaolin, with and without LPS, to cause fibrosis of the TM; (3) quantify ED1+ 
macrophages, laminin and fibronectin deposition in the TM in LPS and LPS+kaolin treated 
eyes; and (4) determined changes in IOP.  
 
3.2 Experimental design 
 
 3.2.1 Pilot study to determine if intracameral kaolin increases levels of laminin and 
 fibronectin in the TM and elevates IOP 
To assess the optimal TM fibrosis inducing kaolin concentration, a single eye from male 
Sprague Dawley rats (175-200g) was intracamerally injected with 5µl of 1.25%, 3.5%, 5%, 
10% or 20% w/v kaolin diluted in 10mM PBS on 0d and 5d. A vehicle of PBS alone (0% kaolin) 
was used as a sham injection for one eye. IOP measurements and TM tissue architecture 
were also analysed in two intact eyes (which received no injections) as negative controls.  
The concentrations of kaolin tested in this study were estimated from those used by Botfield 
et al. (2013) who demonstrated that a 20% w/v of kaolin was sufficient to induce 
inflammation and fibrosis within the brain. Single session IOP measurements were taken 
throughout the 21d experiment.  At 21d anterior segment OCT imaging visualised the angle 
to detect residual kaolin. Following OCT imaging, all rats were killed using increasing 
concentrations of C02, perfused with 4%PFA and the eyes removed and parasagittal sections 
of the eye immunohistochemically qualitatively analysed for TM fibrosis.   
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 3.2.2 Pilot study to determine if LPS with and without kaolin elevates IOP  
  and increases levels of laminin and fibronectin in the TM 
 
On 0d, 8 male Sprague Dawley rats (n=4 eye/group) received a single unilateral 6µl 
intracameral injection composed of 3µl of 0.1g/L LPS and a 3µl 30% w/v kaolin in PBS 
(LPS+kaolin), or, a single unilateral 6µl intracameral injection of 3µl 0.1g/L LPS and 3µl 
intracameral injection of PBS (LPS+PBS). The LPS+PBS group served as a control to assess the 
effects of LPS alone. The concentration of LPS was extrapolated from methods previously 
described (Tsuji et al., 1997; Rosenbaum et al., 2011).  Single session IOP measurements 
were taken at regular intervals throughout the 28d experiment. At 28d all rats were killed 
using increasing concentrations of C02, perfused with 4%PFA and eyes removed for 
immunohistochemical analysis of TM fibrosis determined from parasagittal sections of the 
eye.  Anterior segment OCT imaging was conducted on at 0d and 28d to observe any residual 
presence of kaolin. IOP data were analysed for significance using a repeated measures 
ANOVA. ED1 counts were analysed for significance using Student’s t test (p<0.05). 
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3.3 Results 
 
 3.3.1 Pilot study to determine if kaolin can cause IOP elevation and increase levels of  
 laminin and fibronectin in the TM 
  3.3.1.1 Kaolin (1.25-20% w/v) did not cause a sustained elevation of IOP 
 
Intracameral injection of kaolin at a concentration (w/v) of 1.25% (Figure 3.1a), 2.5% (Figure 
3.1b), 5% (Figure 3.1c), 10% (Figure 3.1c) or 20% (Figure 3.1d) did not achieve sustained 
increases in IOP from the baseline measures (8-12mmHg) recorded from 0% (PBS) and intact 
control eyes. After Intracameral injection of 1.25% kaolin the IOP peaked at 21d at 
13.7mmHg. The average IOP peaked at 13mmHg at 1d for the concentration of 2.5%. Eyes 
injected with 5% w/v kaolin, spiked at 2d reaching 28mmHg and similar single spikes were 
observed with 10% and 20% w/v kaolin, reaching 19mmHg by 6d and 17.3mmHg at 1d, 
respectively.  This pilot data suggests that the kaolin concentrations ranging from 1.25%-20% 
were able to induce transient increases in IOP but were not suitable for causing sustained 
elevations in IOP. 
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Figure 3.1 IOP after intracameral injections of kaolin.  The average IOP is displayed as a 
single point on the graph. The shaded area depicts the normal IOP range. The arrows 
represent the time point of injection at 0d and 5d. IOP for injections of (A) 1.25%, (B)2.5%, 
(C) 5%, (D) 10% and (E) 20% kaolin were measured. No sustained elevations in IOP were 
observed at any concentration of kaolin over the 21d (A-E). Instead there were transient 
increases in IOP observed in the (C) 5%, (D) 10% and (E) 20% but all IOP measurements were 
at similar levels to the intact and PBS control eyes by 21d. 
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  3.3.1.2  Kaolin (20%) accumulation in the iridiocorneal angle  
 
The presence of kaolin in the anterior chamber was observed macroscopically and on 
anterior segment OCT imaging (Figure 3.2). Twenty one days after the 20% kaolin injection at 
0d and 5d, kaolin accumulated in the anterior segment and appeared as opacities in the TM 
in the OCT image. From one eye it was observed that kaolin accumulated towards the 
inferior aspect of the anterior chamber suggesting a gravitational effect had occurred (Figure 
3.2 B Inset). Kaolin accumulation in the angle suggests that the transient kaolin-induced IOP 
spikes observed in the 5%, 10% and 20% eyes may have resulted from temporary 
obstruction of AqH outflow. This contention is supported by the observation that  all other 
kaolin concentrations that had no spikes showed no kaolin accumulation upon macroscopic 
evaluation with  demonstrably clear angles within the anterior chamber on OCT by 21d (data 
not shown). 
 
 
 
 
 
 
 
 
(Figure 3.2 legend on next page) 
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Figure 3.2 Anterior segment OCT imaging of 20% kaolin at 21d 
OCT imaging at 21d of (A) intact eye and (B) eye injected with 20% kaolin at 0d and 5d. The 
intact eye (A) shows normal anterior chamber with a clear angle.  The eye injected with 20% 
kaolin (B) shows the white opacities characteristic of an accumulation of kaolin in the angle. 
Inset shows meridian of OCT section. 
 3.3.1.3  Kaolin did not alter TGF-β, laminin or fibronectin levels in the TM compared to 
  intact or PBS controls  
Qualitative analysis (performed by two independent observers) of total TGF-β 
immunoperoxidase staining of 8-12 sections from the vertical meridian of each eye detected 
no changes in staining between the intact eye and eyes injected with 0% (PBS only), 5% or 
20% kaolin concentrations (Figure 3.3). Cytoplasmic TGF-β staining was localised within the 
ciliary body, iris , TM and sclera. These data show that increasing concentrations of kaolin 
did not alter the endogenous levels of total TGF-β within the angle. Laminin staining was also 
present at similar levels across all groups (Figure 3.4). Laminin was observable as long thin 
strands within the TM and at varying thickness in a discontinuous fashion around Schlemm’s 
canal.  Fibronectin levels were very low in all eyes and no observable differences were 
apparent between groups (data not shown).  
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Figure 3.3 TGF-β staining at experimental 21d. 
Parasagittal eye sections illustrating total TGF-β staining in the iridiocorneal angle of the 
anterior chamber (AC). (A) Diagram to show region of interest. (B) Negative reagent control 
(no primary antibody). (C-F) Representative images of TGF-β staining in the kaolin injected 
eyes. There was intense cytoplasmic staining in the ciliary body (CB) and iris in the intact (C) 
0% (D) 5% (E) and (F) 20%. Lower levels of staining were observable in all groups in the TM. 
There were no differences in total TGF-β levels between the groups (C-F). Scale bar – 100µm; 
CB – Ciliary body; SC – Schlemm’s Canal; AC – anterior chamber; * trabecular meshwork. 
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(Figure 3.4 legend on next page)   
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Figure 3.4 Laminin deposition in the TM. Parasagittal eye sections illustrating laminin 
staining (red) in the iridiocorneal angle of the anterior chamber (AC). (A) over exposed image 
to show the angle containing the TM and Schlemm’s canal  (located between white lines). (B-
H) Representative images of laminin staining in the kaolin injected eyes. Similar levels of 
laminin staining (red) were observed within the ciliary body (CB), TM, cornea and iris in the 
(B) intact and (C) 0%, (D) 1.25%, (E) 2.5%, (F) 5%, (G) 10% and (H) 20% kaolin injected eyes. 
In all groups (B-H), laminin deposition around Schlemm’s canal was discontinuous and was 
less visible on the inner wall (towards the TM) compared to the outer wall. Scale bar – 
100µm; CB – Ciliary body; SC – Schlemm’s canal; TM – trabecular meshwork; AC – anterior 
chamber. 
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3.3.2 Pilot study to determine if LPS±kaolin(30%) can cause IOP elevation and increase 
 levels of laminin and fibronectin 
  3.3.2.1  Intracameral injection of LPS+kaolin(30%) induced transient increases 
   in IOP compared to LPS+PBS but not a sustained an elevation in IOP 
 
Intracameral injection of LPS+30%kaolin transiently increased IOP between 1d and 7d 
(Figure 3.5). A single intracameral injection of LPS+30%kaolin significantly elevated IOP  
(p<0.05) compared to the LPS+PBS group reaching an average of 20±0.9mmHg at 1d and 2d. 
By 3d the average IOP was lower at 11.3±1mmHg, similar to the IOP in the LPS+PBS group. 
By 4d IOP significantly increased again to 21.8±1.7mmHg (p<0.05) and remained elevated 
until 7d at a mean IOP of 21.2±mmHg. After 7d the IOP returned to baseline levels of 
10.1±0.5mmHg and stayed there until 28d. The LPS+PBS group remained within normal 
levels throughout the 28d period, varying between 8.25±0.2mmHg and 11.42±0.4mmHg. 
Interestingly, the IOP data were significantly higher (p<0.05) in the LPS+kaolin group 
compared to LPS+PBS from transient peaks but both values were within the normal range at 
the end of the experiment.  
These data suggest that LPS+30%kaolin induced acute spikes in IOP, which was compared to  
the lower concentrations of kaolin used in the pilot study, in which a sustained increase in 
IOP was not achieved. 
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Figure 3.5 IOP measurements after LPS+30%kaolin and LPS+PBS. The average IOP±SEM is 
displayed here as a single point on the graph. The shaded area represents normal IOP range. 
Intracameral injections were given on 0d. Compared to PBS+LPS, transient elevations in IOP 
were observed between 1d and 7d in the LPS+30%kaolin group with a return to normal IOP 
measurements between 7d and 28d.  IOP were significantly higher (p<0.05) in the 
LPS+kaolin(30%) compared to the LPS+PBS group on 1d, 2d, 4d and 21d. Mean IOP values 
remained within the normal range for the eyes injected with PBS+LPS.  
 
 
 
 
 
 
* 
* 
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 3.3.2.2  Anterior segment OCT imaging detected 30%kaolin in the angle 
 
Before injections the anterior chamber angles were clear on OCT images (Figure 3.6A). At 
28d after LPS+30%kaolin injections, the presence of kaolin in the anterior chamber was 
observed macroscopically (not shown) and on anterior segment OCT imaging in 2 out of 4 
eyes (Figure 3.6B). All eyes injected with LPS+PBS were devoid of opacities in the angle on 
OCT (data not shown). The presence of kaolin in the angle 28ds after injection shows that it 
is not completely cleared from the eye and thus could have attributed to the acute IOP 
spikes observed between 1d and 7d (Figure 3.5). However, as the IOP levels returned to 
baseline, any resistance to outflow was most likely restored through the movement of kaolin 
from the drainage site so that AqH outflow was normalised.   
 
 
Figure 3.6 Anterior segment OCT imaging of LPS+30%kaolin at 28d 
Anterior segment OCT imaging (A) before intracameral injection showing the normal 
anterior chamber with a clear angle and (B) 28d after intracameral injection of 
30%kaolin+LPS showing an accumulation of white opacities of kaolin (circled on image) in 
the angle. 
A B 
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 3.3.2.3  LPS+30%kaolin did not alter TGF-β, laminin or fibronectin levels in the TM but 
  did increase the number of ED1+ cells compared to LPS+PBS  
 
Qualitative analysis of total TGF-β immunoperoxidase staining detected no apparent change 
in levels of staining between LPS+30%kaolin and LPS+PBS groups (Figure 3.7). As with the 
kaolin pilot data (Figure 3.3), intense cytoplasmic TGF-β staining was localised within the 
ciliary body and iris and less intensive staining was observed in the TM and sclera. Non-
specific staining was found in both groups in the form of dark brown spherical cellular 
deposits localised to inflammatory cells. These data suggest that the addition of kaolin to LPS 
injections did not alter the endogenous levels of total TGF-β within the angle. Laminin was 
present within the ECM at similar levels in both LPS+PBS and LPS+30%kaolin groups (Figure 
3.8), observable as long thin strands within the TM and at varying thickness in a 
discontinuous fashion around Schlemm’s canal. Similar low extracellular fibronectin levels 
were seen in LPS+30%kaolin and LPS+PBS groups (data not shown). 
91 
 
 
(Figure 3.7 legend on next page) 
 
A B C 
D E F 
IRIS 
IRIS 
IRIS 
IRIS 
IRIS 
IRIS 
TM 
TM 
TM 
TM 
TM 
TM 
AC 
AC 
AC 
AC 
AC 
AC 
CB 
CB 
CB 
CB 
CB 
CB 
SC SC 
SC 
SC 
SC 
 
9
1
 
92 
 
Figure 3.7 TGF-β staining at experimental 28d. Parasagittal eye sections illustrating TGF-β 
staining of the anterior chamber (AC) iridiocorneal angle. (A-C) Representative images of 
TGF-β staining in the LPS+PBS injected eyes, and (D-F) in the LPS+kaolin(30%) injected eyes. 
There was intense cytoplasmic staining in the ciliary body (CB) and iris in the intact and lower 
levels of staining was observed in all groups in the TM but no differences between the 
groups were identified.  Dark brown spherical staining was also observed in both groups 
(illustrated by the arrow in panels A, D, E and F) possibly associated with the presence of 
macrophages.  Scale bar – 100µm; CB – Ciliary body; SC – Schlemm’s canal; TM – trabecular 
meshwork; AC – anterior chamber. 
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Figure 3.8 Laminin deposition in the TM at 28d. Parasagittal eye sections illustrating laminin 
staining of the anterior chamber (AC) in the iridiocorneal angle. Representative images of 
laminin (red) staining in the (A) LPS+PBS and (B) LPS+30%kaolin injected eyes. Similar levels 
of laminin staining were observed within the ciliary body (CB), TM and iris in both groups. In 
addition, both groups showed discontinuous laminin deposition around Schlemm’s canal 
(SC) with less intense laminin in the wall juxtaposed to the TM compared to that opposed to 
it (*). Scale bar – 100µm; CB – Ciliary body; SC – Schlemm’s canal; TM – trabecular 
meshwork; AC – anterior chamber.  
A 
B 
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Interestingly, in one LPS+30%kaolin eye there was a mass accumulation of particles and cells 
that were positive for fibronectin in their cytoplasm, shown by a circular staining pattern 
around the nucleus (Figure 3.9A). Extracellular laminin staining was also shown with in the 
particulate mass (Figure 3.9A).  The IOP for this eye were particularly high (>25mmHg) within 
the first 7d after injection.  TGF-β staining was also observed within this accumulation of 
cells/particles as dark brown/grey mass with a circular cell shape (Figure 3.9 B). This suggests 
that in this animal a large residual kaolin deposition was present in the anterior chamber in 
at 28d. It is important to note that the mass accumulation seen here was an isolated 
incidence and was not seen in the other eyes on OCT.  
There was an significant (p<0.05) increase in the number of ED1 cells in the TM seen in all 
eyes in the LPS+30%kaolin group compared to LPS+PBS group (Figure 3.9C-E) suggesting that 
the combination of LPS and 30%kaolin caused more inflammation than LPS alone.  
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Figure 3.9 Effects of LPS+30%kaolin on ED1 macrophage infiltration. Parasagittal eye 
sections of the angle showing mass infiltration of cells in the LPS+30%kaolin identified by: (A) 
cellular fibronectin (green), extracellular laminin staining (red) and DAPI staining was used to 
identify cell nuclei (blue); and (B) Total TGF-β staining is seen as brown/grey particulate in 
the same region. (C) Representative image showing ED1
+
 cells (green) in the angle of the 
LPS+PBS group and (D) LPS+30%kaolin group. White arrows show example of positive cells. 
(E) Graphical representation showing there were significantly more ED1
+
 cells in the TM after 
LPS+30%kaolin injections compared to LPS+PBS injection groups (p<0.05, n=4). Scale bar – 
100µm; SC – Schlemm’s canal; TM – trabecular meshwork.  
In summary, these data suggest that the injection of LPS to 30%kaolin led to early peaks in 
IOP that returned to normal levels after the first week. The addition of LPS caused an 
infiltration of ED1
+
 exacerbated specifically by 30% kaolin compared to LPS alone. However, 
despite inducing an inflammatory microenvironment, fibrosis within the TM was not 
established and there were no sustained increases in IOP.  
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3.4 Discussion 
 
 3.4.1 Kaolin pilot study 
The aim of this study was to develop a sustained increase in IOP after inducing TM fibrosis 
using intracameral injections of kaolin. Kaolin injections into the basal cisterns induces 
endogenous raised levels of TGF-β causes fibrosis in the sub-arachnoid space in the rat brain 
(Botfield et al., 2013) and therefore this suggested that it would be a suitable candidate 
fibrogenic agent in the eye. To find the concentrations favourable to induce TM fibrosis,  a 
number of concentrations up to the 20% used by Botfield et al. (2013) were intracamerally 
injected and IOP was monitored. In addition to its fibrogenic properties, kaolin may also act 
as a plug and obstruct AqH from draining through the TM. The aim of the study was to 
induce fibrosis of the TM using kaolin at a concentration which avoids obstructions of TM 
drainage and increases in IOP, so lower concentrations were tested than those by Botfield et 
al. (2013).  A sustained increase in IOP was not induced at any of the kaolin concentrations 
up to 20%, although there were random peaks in IOP within the 2-3d after injections in the 
eyes injected with 5%, 10% and 20% kaolin probably caused by kaolin temporarily blocking 
outflow, an assertion supported by macroscopic and OCT imaging of kaolin opacity in the 
anterior chamber. In addition, the rapid return of IOP to normal range suggested there were 
no permanent changes to AqH outflow, indicative of TM fibrosis. The nature of AqH 
dynamics results in its very high turnover rate, therefore it is possible that kaolin was 
completely cleared from the anterior chamber before it caused any noticeable inflammation 
or fibrosis within the angle. However, there was slight an accumulation of residual kaolin 
within the angle at 21d in the 20% kaolin eye despite the IOP being within normal range. This 
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suggests that the kaolin concentrations used in this study were not enough to cause 
inflammation. This failure of kaolin >20% at these concentrations to cause sustained 
elevations in IOP correlated with an absence of fibrosis of the TM. It was expected that 
endogenous levels of TGF-β would increase following administration of kaolin (as shown 
with Botfield et al., 2013) and this increase in TGF-β would, in part, lead to fibrogenesis in 
the TM through increasing deposition of ECM proteins including laminin and fibronectin.  
Only total TGF-β levels were measured in this study, therefore, levels of active TGF-β may 
have altered with injections of kaolin and/or LPS. Measuring active TGF-β levels would be 
required in future studies to demonstrate any changes. However, the failure of TGF-β, 
laminin or fibronectin levels to change between the intact eyes and the eyes injected with 
kaolin demonstrated that fibrosis within the TM had not occurred. Thus kaolin was not a 
suitable TM fibrogenic agent because in an immune privileged area such as the eye, it may 
be that kaolin  is inert. Therefore it was hypothesised that administration of LPS (a potent 
immune cell activator) combined with an increased concentration (30%) of kaolin would 
induce a more robust inflammatory response, evidenced by increases in total TGF-β and 
other pro-inflammatory cytokines and TM fibrosis. TM fibrosis would also be reflected by a 
sustained elevation in IOP.  
  
 3.4.2 LPS±30%Kaolin pilot study 
LPS alone or combined with 30%kaolin did not induce a sustained increase in IOP and did not 
result in fibrosis of the TM. The combination of LPS and 30%kaolin did show an increased 
number of ED1
+
 macrophages, compared to LPS alone, suggesting that kaolin did exacerbate 
the inflammatory response in this model. However, the increase in ED1
+
  macrophages in 
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this group was not enough to cause a sustained rise in IOP. This suggests that the increase in 
macrophage numbers was not sufficient to alter the resistance of the TM enough to reduce 
AqH outflow. 
 As with the kaolin pilot studies, transient increases in IOP occurred within the first week 
after the single intracameral injections at 0d. OCT imaging detected the presence of residual 
kaolin within the anterior chamber of some eyes, despite IOP returning within the normal 
range by the end of the experiment at 28d. The reason for the transient increases in IOP was 
unclear but could be attributed to the clearance of kaolin.  
 
Another consideration is the vascular permeability alterations induced by LPS. LPS causes 
vessels to become leaky, permitting the entry of immune cells and causing alterations in 
fluid levels within the anterior chamber. It is possible that the IOP peaks occurring after the 
increased levels of kaolin were negated by the altering permeability of vessels caused by 
LPS. In support of this proposition, the IOP did drop towards the lower end of normal in the 
LPS only group.   The transient IOP peaks were only observed in the LPS+30%kaolin injected 
eyes, suggesting an acute phase IOP altering effect of kaolin.   
 
The inherent variability of IOP, together with the measurements returning to normal levels, 
suggested that AqH outflow was not significantly restricted and therefore, fibrosis of the TM 
had not been established. Indeed, this was supported with qualitative immunohistochemical 
analysis of the angle.  Endogenous total TGF-β, laminin and fibronectin levels showed no 
differences between eyes injected with LPS and those injected with LPS+30%kaolin. These 
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two groups also demonstrated similar levels of TGF-β, laminin and fibronectin levels to that 
seen in the intact eye from the qualitative analysis in the kaolin pilot studies.    
 
The ability of LPS to cause cellular infiltration into the anterior chamber was successfully 
modelled in this study. The immunoperoxidase staining for total TGF-β showed a uniform 
cellular/particulate mass embedded within the angle. The staining of this mass yielded a very 
dense brown/grey stained area that was thought to be an accumulation of mostly kaolin. 
Further analysis showed densely stained fibronectin uniformly distributed in a circular 
manner within this accumulation of cells/kaolin particles. Laminin deposition was also 
observed in a peri-cellular arrangement throughout the mass.  
 
 3.4.3 Conclusion 
In summary, the data from these pilot studies evaluating the use of kaolin alone or in 
conjunction with LPS to induce TM fibrosis led to the conclusion that kaolin was not suitable 
as a fibrogenic agent in the anterior chamber. However, there are important considerations 
to note with regards to the experimental design used in this study. Perhaps longer time 
course experiments and more frequent intracameral injections would have shown more 
favourable results. In addition, the IOP monitoring was not continuous and therefore data 
with regards to IOP levels may have been missed. Continuous pressure monitoring would 
have overcome this limitation but would have been a more invasive procedure.  This model 
was useful to show the inflammatory effects of LPS and to induce transient increases in IOP 
when LPS is combined with kaolin, but due to the lack on ECM deposition in both groups, 
this model was deemed unsuitable to induce TM fibrosis and sustained IOP elevations.  
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Chapter 4 
 
TGF-β induced Trabecular Meshwork 
Fibrosis, IOP elevations and  
RGC death  
 
102 
 
 
4.1 Rationale 
 
POAG is a multifactorial disease featuring fibrosis within the anterior chamber of the eye 
(Tripathi et al., 1994). The main and only modifiable risk factor is increasing levels of IOP 
(Quigley et al., 1980; Sommer et al., 1991). Elevations in IOP are thought to occur from 
fibrosis of the TM preventing drainage of AqH (Junglas et al., 2012).  Elevated increases in 
IOP are correlated with RGC death (Morrison et al., 1998). Although no single experimental 
paradigm mimics all of the known pathobiology in POAG, in vivo rodent models are useful to 
investigate biological aspects of the disease in isolation. The pathobiology of glaucoma is 
routinely investigated using rodent models of IOP elevation (reviewed by Johnson & 
Tomarev, 2010). However, until recently there were few rodent models available to 
investigate TM fibrosis specifically. The most notable study of TM fibrosis was by Junglas et 
al., (2012) who successfully demonstrated TM fibrosis in mice through gene mediated up-
regulation of TGF-β signalling. New more disease-related means of generating TM fibrosis 
are needed that create a sustained elevation in IOP and consequent RGC death. Such 
experimental tools would then enable investigations into the efficacy of potentially 
therapeutic anti-fibrotic agents.  
 
 TGF-β is a potent fibrogenic agent implicated in TM fibrotic diseases (Junglas et al., 2012; 
Fuchshofer et al., 2014).  Over-expression of TGF-β1 increases TM fibrosis and elevates IOP 
(Junglas et al., 2012).  Patients with open angle glaucoma have high levels of TGF-β1 in the 
AqH, associated with pseudoexfoliation glaucoma (Schlötzer-Schrehardtl et al., 2001), and 
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TGF-β-2, associated with primary open angle glaucoma (Tripathi et al., 1994) compared to 
age-matched controls.  
 
The ability of exogenous TGF-β1 and 2 to mimic the disease-related pathology to increase 
fibrosis of the TM were studied in this thesis to test the hypothesis that increasing levels of 
TGF-β1/2 in the AqH leads to TM fibrosis, sustained IOP elevations and RGC death.   
 
4.2  Experimental design 
   
 4.2.1 Study 1 - Effects of general vs local anaesthetic on IOP 
 
To investigate the effects of general anaesthesia on IOP, IOP recordings studies under both 
local and general anaesthesia were conducted. On 3 successive days rats were given either 
5% Isoflurane by inhalation (n=3) or topical eye drops of Minims Oxybuprocaine 
Hydrochloride 0.4% w/v (n=3) and IOP measured by tonometry. Rats receiving local 
anaesthetic were habituated to handling one week before and manually restrained during 
IOP recordings. IOP data were analysed for normality, followed by testing for significance 
(p<0.05) using the within-subjects repeated measures design.   
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 4.2.2 Study 2 - Optimising the TGF-β dosing regimen to sustain elevated IOP  
   
A pilot study comprised control rats (n=3) intracamerally injected with PBS and rats treated 
with active TGF-β1 (n=3) at 0.5ng/ml on 4d and 11d then 5ng/ml on 18d and 49d and IOP 
monitored  over a 55 day period (Figure 4.1).  Baseline IOP readings were taken on 0d. IOP 
measurements were taken between 9-11am on days 0, 4, 6, 11, 13, 18, 25, 27, 31, 35, 42, 49 
and 55. IOP measurements were taken before intracameral injections to avoid immediate 
post-operative spikes in IOP. IOP data were analysed for normality, followed by testing for 
significance (p<0.05) using the within-subjects repeated measures design.   
 
 
Figure 4.1 Experimental design for testing TGF-β1 dosing regimen. 
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 4.2.3  Study 3 - Testing the effects of Latanoprost on the TGF-β induced increase in 
  IOP 
 
IOP in rats over a period of 0-45d was elevated by intracameral injections of 5ng/µl of TGF-
β1 at 10d, 33d and 35d to investigate if topical administration of latanoprost (Xalatan™), a 
well-known IOP lowering agent, attenuated the TGF-β induced elevations in IOP (Figure 4.2). 
The IOP was monitored at 0d, 6d, 10d, 14d, 21d, 30d, 35d, 40d, 42d and 45d. Rats (n=8) 
received unilateral intracameral injections of PBS (n=8 eyes) or 5ng/µl TGF-β1 (n=8 eyes). 
Each of the PBS and TGF-β groups were subsequently administered one drop of 0.005% 
latanoprost (n=4) or PBS eye drops (n=4) once a day from experimental days 35-45.  IOP data 
were analysed for normality, followed by testing for significance (p<0.05) using generalised 
estimated equations.   
 
Figure 4.2 Design of experiment to investigate the effects of an IOP lowering eye drop 
(latanoprost) to attenuate the IOP rise induced by intracameral injections of TGF-β1. 
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 4.2.4   Study 4 - Sustained increase in IOP, TM fibrosis and RGC death by   
  intracameral injections of TGF-β1 
 
Bi-weekly intracameral injections of TGF-β1 (n=6 eyes), PBS (n=6 eyes) or TGF-β1/PBS (n=6 
eyes) were given and IOP measured by tonometry as described in Section 2.2 (Figure 4.3). All 
rats were killed at 30d. Laminin immunohistochemistry of the TGF-β1 (n=3 eyes), PBS (n=3 
eyes) and TGF-β1/PBS (n=6 eyes) injected eyes determined levels of ECM deposition around 
Schlemm’s canal. RGC that were βIII-tubulin
+
 were counted in 250µm linear tracts of the 
retina from parasagittal sections to assess RGC death.  RGC counting from whole mounted 
retina labelled with 4% FluoroGold was also performed on the TGF-β1 (n=3 eyes) and PBS 
(n=3 eyes) injected eyes. IOP data were analysed for normality, followed by testing for 
significance (p<0.05) using the within-subjects repeated measures design.  The Student’s 
paired t test was used for statistical analysis of TM fibrosis and RGC survival. 
 
Figure 4.3 Design of experiment for intracameral injections of TGF-β1 to induce fibrosis, 
IOP elevation and RGC death.  
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 4.2.5 Study 5 - Sustained increase in IOP, TM fibrosis and RGC death using TGF-β2 
 
Bi-weekly intracameral injections of TGF-β2 (n=12 eyes) or PBS (n=12) were administered as 
described in Section 2.2 (Figure 4.4). Bi-weekly IOP was measured by tonometry throughout 
the 30d. Functional analysis of the retina and visual pathway using VEP was performed 
before rats were killed on 30d. Laminin and fibronectin immunohistochemistry in the TM 
(n=4) and electron microscopy (n=4) determined induction of TM fibrosis. RGC counting 
from whole mounted retina labelled with 4% FluoroGold was also performed on the TGF-β2 
(n=4 eyes) and PBS (n=4 eyes) injected eyes. IOP data were analysed for normality, followed 
by testing for significance (p<0.05) using the within-subjects repeated measures design.  The 
Students paired t test was used for statistical analysis of TM fibrosis and RGC survival. 
 
 
Figure 4.4 Design of experiment for intracameral injections of TGF-β2 to induce fibrosis, 
IOP elevation and RGC death.  
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4.3 Results 
 
 4.3.1 Study 1 - General compared to local anaesthetic lowered IOP  
The administration of a general anaesthetic significantly lowered the overall mean IOP of 
11.6±0.5 mmHg from 3 separate recordings at 0d, 9d and 13d compared to local anaesthetic 
(p<0.05), which had a mean IOP of 14.8±0.55mmHg (Figure 4.5). The individual IOP 
recordings over the 3 separate days under general anaesthetic were 10.9±0.3, 11.3±.4 and 
12.6±0.3 mmHg and under local anaesthetic were 15.9±1.6, 14.1±0.3 and 14.3±0.01mmHg. 
These data demonstrate that general anaesthetic lowers the IOP compared to local 
anaesthetic which was maintained at each time point throughout the experiment. Manual 
restraint used under local anaesthesia caused some distress to the rats and was time 
consuming when compared to general anaesthetic and so IOP was measured under general 
anaesthesia subsequently. 
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Figure 4.5 Effects of IOP after local and general anaesthesia. (A) On 0d, 9d and 13d the IOP 
measurements were lower after general than after local anaesthesia. However, the 
difference was only significantly lower on 0d (p<0.05); (B) the mean IOP of the pooled data 
from the 3 daily readings were significantly lower after general than local anaesthesia 
(p<0.05).  
A 
B 
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 4.3.2 Study 2 - Optimising TGF-β dosing regimen to cause sustained increase  
  in IOP  
 
 
IOP were recorded after 2 injections of TGF-β1 at 0.5ng/µl between 0-17d and 2 further 
injections of 5ng/µl between 18-49d to ascertain the optimal dose and injection regime to 
use in further studies.  There was no sustained elevation in IOP with intermittent injections 
of TGF-β1 at either 0.5ng/µl or 5ng/µl (Figure 4.6). At 0.5ng/µl after injections on 0d and 11d 
the IOP remained at baselines levels i.e. 9.4±0.1-13.2±2.5mmHg, a range which was not 
significantly different from control IOP of 9.1±0.6 and 11.9±0.9mmHg.  Interestingly, 
between 18-31d and 49-55d the higher dose of 5ng/µl TGF-β trended towards higher IOP 
values of up to 15.5±1.3mmHg but this difference did not reach  statistical significance when 
compared to PBS. These data suggest: (1) a dose of 0.5ng/µl was not sufficient to increase 
IOP above baseline and PBS controls; and (2) the marginal efficacy of the higher dose of 
5ng/µl over a period of 9 days suggesting that it could be given more frequently to sustain 
the raised IOP.   
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Figure 4.6 IOP measurements after specific concentrations of TGF-β1 injections. The 
mean±SEM IOP is displayed here as a single point on the graph. The arrows represent the 
dose and day of injections. No sustained elevations in IOP were observed at either 
concentrations of TGF-β1 or in the PBS controls. IOP in the higher dose TGF-β did spike after 
injections between 25-35d but significantly higher than control PBS injected eyes.  
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 4.3.3 Study 3 – Repeated TGF-β injections induced a sustained increase in IOP  
  which could be attenuated by latanoprost  
 
The aim of this experiment was to investigate IOP after injections of TGF-β1 at 5ng/µl on 
10d, 30d and 35d with and without the IOP lowering eye drop, latanoprost, from 30-45d. In 
both PBS and TGF-β groups, IOP levels remained at normal levels of 9 and 13mmHg between 
0-21d showing that the single injection of TGF-β on day 10 did not cause IOP to increase 
(Figure 4.7). Decreasing the interval between TGF-β injections, by administering on 30d and 
35d led to a significant (p<0.05), and sustained, increase in IOP from 13.4±1mmHg at 30d to 
17±1.6mmHg at 45d, compared to PBS which was at 13.9±1.7 at 30d and at 11.2±0.9 at 45d. 
The elevated IOP shown in the TGF-β group after 30d was significantly (p<0.05) lowered by 
the topical administration of latanoprost from 30-45d, so that the IOP in TGF-β1+latanorpost 
group remained within the normal range of 11-12mmHg.  
This data suggests that more frequent injections of TGF-β led to a sustained increase in IOP 
compared to PBS and that this raised IOP is lowered through the use of a commonly 
prescribed IOP lowering agent to increase AqH outflow through the uveoscleral tract.  
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Figure 4.7 IOP measurements after TGF-β1 injections and latanoprost eye drops. Three IOP 
measurements were taken to provide an average reading/eye. The average IOP is displayed 
here as a single point on the graph±SEM. The arrows represent the day of injections and eye 
drop administration. A single injection of TGF-β did not lead to a sustained increase in IOP 
compared to controls between days 10-30. A biweekly injection regime of TGF-β caused a 
sustained increase in IOP between days 30-45 compared to controls. This TGF-β induced IOP 
increase was significantly reduced by the topical application of latanoprost reducing IOP to 
those in the control groups (p<0.05). 
 
 
 
 
 
114 
 
 
 4.3.4 Study 4 - TM fibrosis, sustained IOP elevation and RGC death after  
  intracameral TGF-β1 injections 
   4.3.4.1 Bi-weekly intracameral injection of TGF-β1 led to sustained  
    elevations in IOP  
 
Compared to PBS, bi-weekly injections of 5ng/µl TGF-β1 increased IOP (Figure 4.8) although, 
the difference did not reach statistical significance until 10d, where IOP remained within 
normal range of 9.7±0.4mmHg-11.1±0.6mmHg in the PBS injected eyes and 10.4±0.4mmHg -
12.6±0.77mmHg in the TGF-β1 injected eyes. Between 10-30d the difference in IOP 
increased so that after TGF-β1 injections a sustained level of 14.6±0.9mmHg was achieved 
becoming statically (p<0.05) elevated above the normal range of 10.6±0.7mmHg-
11.8±0.6MmHg.  The sustained increased in IOP (Figure 4.8) demonstrated that TGF-β1 had 
caused sustained higher level of IOP probably attributable to AqH outflow impairment.  
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Figure 4.8 IOP measurements after TGF-β1 injections. The average IOP±SEM is displayed 
here as a single point on the graph.  There was a sustained increase in IOP observed after 
injections of TGF-β compared to PBS from 10d to the end of the experiment at 30d (p<0.05).  
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Another group of rats received TGF-β1 injections for 17 days when the IOP plateaued at 
13.9±1.38mmHg, thereafter, received intracameral injections of PBS only (TGF-β10-17d/PBS21-
30d) where the IOP continued to rise to a measurement of 16.7±1.3mmHg by 30d. TGF-β10-
17d/PBS21-30d  study was designed to confirm that it was not just continual injections of 
exogenous TGF-β that was maintaining the higher level IOP but that the earlier injections of 
TGF-β were sufficient to cause fibrosis in the TM and hence a sustained resistance to AqH 
outflow. Indeed, the data (Figure 4.9) demonstrated that the TGF-β1 induced rise in IOP was 
maintained until the end of the experiment at 30d, despite cessation of TGF-β1 injections 
17d.  
 
IOP after TGF-β10-17d/PBS21-30d injections were significantly higher than the PBS control group 
on 24d, 28d and 30d (p<0.05) suggesting that the induced rise in IOP was not from the 
continued repeated injections of TGF-β1 and that the sustained increase was induced 
successfully within the first 17 days, probably from inducing a permanent restriction to AqH 
outflow.  
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Figure 4.9 IOP measurements after TGF-β10-17d/PBS21-30d injections. The mean IOP±SEM is 
displayed here as a single point on the graph.  There was a sustained higher level of IOP 
observed from 17d until 30d despite cessation of TGF-β1 injections on 17d. The IOP were 
significantly higher than PBS from 24d until 30d (P<0.05).  
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  4.3.4.2  Repeated intracameral administration of TGF-β1 increased 
    laminin deposition in inner wall of Schlemm’s canal 
 
Laminin deposition staining was especially prominent around in the basement membrane 
surrounding Schlemm’s canal in the TGF-β-injected eyes compared to the PBS-injected eyes 
(Figure 4.10). In the PBS groups, the laminin staining was observed as a discontinuous 
pattern localised mainly to the outer wall of Schlemm’s canal (towards the sclera) whereas, 
the inner wall of Schlemm’s canal (towards the TM) had very little laminin deposition (Figure 
4.10a). In the TGF-β group, laminin was deposited in a continuous band around Schlemm’s 
canal of equal thickness in the outer and inner walls (Figure 4.10b). Quantitation of this 
observation using pixel counts demonstrated that TGF-β0-30d and TGF-β0-17d/PBS21-30d injected 
eyes had significantly (p<0.001) more laminin staining around Schlemm’s canal compared to 
the PBS0-30d injected eyes.   These data show that by 30d, TGF-β1 increased laminin 
deposition around Schlemm’s canal, both when injected bi-weekly from 0-30d and 
importantly, when injections were stopped at 17d suggesting that increase ECM deposition 
had contributed to increased “stiffness” or “resistance” leading to the sustained IOP 
elevation shown in these eyes.  
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Figure 4.10 Distribution of laminin around Schlemm’s canal. Parasagittal eye sections illustrating laminin staining in the iridiocorneal 
angle (*) and inset image of Schlemm’s canal. Laminin deposition was found around Schlemm’s canal in both (A) PBS and (B) TGF-β1 
injected eyes. (C) Bi-weekly injections of TGF-β from 0-30d (n=3) and 0-17d (n=6) led to significant (p<0.001) increase laminin deposition 
within the outer and inner walls of Schlemm’s canal, which were at minimal levels in the PBS group (n=6). Scale bar – 100µm; CB – Ciliary 
body; SC – Schlemm’s canal; TM – trabecular meshwork; AC – anterior chamber.  
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  4.3.4.3  Repeated intracameral injections of TGF-β1 and RGC death 
 
Β-III tubulin
+
 RGC counts from retinal sections showed and 8% loss of RGC at the optic nerve 
head (i.e. 92±2% compared to PBS counts of 100±5%) compared to the peripheral retina but 
was not significantly lower (Figure 4.11 A).  The peripheral RGC counts demonstrated no 
statistical difference in numbers between the PBS or the TGF-β1 group at 91±7% and 91±3%, 
respectively.  These data showed that RGC death trended towards a preferential loss at the 
optic nerve head compared to the peripheral retina.  In the TGF-β0-17d/PBS21-30d group there 
was 13% loss of RGC compared to the PBS group which was not significant (Figure 4.11 B). 
Interestingly, FG
+
RGC counts from whole mounted retina demonstrated a significant (n=3, 
p<0.01) 27% loss in RGC in the TGF-β1 injected eyes compared to PBS group (Figure 4.12). 
These data suggest that RGC death occurred, although there was a discrepancy in the level 
of RGC death measure from retinal sections vs retinal whole mounts.   
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Figure 4.11 RGC counts from retinal sections. Data points are the mean %RGC±SEM from 
intact retinal counts. (A) The preferential loss of RGC at the optic disc compared to the retina 
close to the iris (periphery) after injections of TGF-β was not significant.  (B) RGC counts from 
the retina close to the optic nerve head showed that TGF-β1 and TGF-β0-17d/PBS21-30d groups 
had less RGC compared to intact and PBS injected eyes by 30d but this did not reach 
significance.  
A 
B 
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Figure 4.12 RGC counts from whole mounted retinae. Mean number of RGC±SEM from the 
TGF-β1 and PBS groups. By 30d there was 27% loss of RGC in the TGF-β1 group compared to 
PBS (n=3, ***p<0.01).  
 
In summary, these data showed that the increasing levels of TGF-β1 in the AqH increased the 
deposition of laminin, increased and maintained an elevated IOP (that was not dependent 
on continued administration of exogenous TGF-β) and resulted in 27% RGC death (from 
retinal whole mount data only).   
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 4.3.5 Study 5 - TM fibrosis, sustained IOP elevation and RGC death after  
  intracameral injections of TGF-β2 
    
   4.3.5.1 Bi-weekly intracameral injection of TGF-β2 led to a sustained  
    elevation in IOP  
 
Compared to PBS and as with injections of TGF-β1, bi-weekly injections of 5ng/µl TGF-β2 
increased IOP (Figure 4.13) although, the difference did not reach statistical significance until 
7d before which, the IOP remained within a normal range of 10.4±0.3mmHg -12.4±0.7mmHg 
in the TGF-β2 injected eyes. From 7d until 30d IOP increased and was maintained at a higher 
level after TGF-β2 injections to 14±0.3mmHg.  IOP in the TGF-β2 injected eyes was 
significantly higher (p<0.05 between 9d and 14d; p<0.001 between 16d and 30d) than in the 
PBS injected eyes, which remained within normal range of 10.5±0.4mmHg-11.7±0.3MmHg.  
The sustained increased in IOP (Figure 4.13) demonstrated that TGF-β2 is a suitable agent to 
cause a restriction in AqH outflow as represented by a sustained higher level of IOP. 
Interestingly, the IOP levels for TGF-β2 were consistent with those recorded after similar 
injections of TGF-β1.  
 
 
 
124 
 
 
 
Figure 4.13 IOP measurements after intracameral injection of TGF-β2. The average IOP is 
displayed here as a single point on the graph±SEM.  There was a significant and sustained 
higher level of IOP observed after injections of TGF-β2 compared to PBS (*p<0.05; *** 
p<0.001). 
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  4.3.5.2  Bi-weekly intracameral injections of TGF-β2 causes TM fibrosis 
 
Intracameral injection of TGF-β2 led to fibrosis in the TM (Figure 4.14). In the intact and PBS 
injected eyes, immunostaining for laminin was observed in the ciliary body, iris and in 
vascular basement membranes and was dense around Schlemm’s Canal in the outer wall but 
thinner in the inner wall. Laminin staining was also present at very low levels within the TM, 
but when present, was observed as thin linear strands throughout the meshwork. By 30d, 
after bi-weekly injections of TGF-β2, laminin levels had significantly increased throughout 
the TM (p<0.001), being especially prominent in the JCT region of the TM and in the inner 
wall of Schlemm’s Canal, compared to intact and PBS injected eyes.   By 30d, the TM was 
also densely packed with fibronectin deposits compared to intact and PBS injected eyes 
(P<0.001).   
TEM of parasagittal sections of the eyes revealed increased ECM deposition (Figure 4.15). In 
the JCT region of PBS eyes there was an irregular organisation of trabecular cells. Intra-
trabecular spaces could be identified along with thin strands of basement membrane and 
electron dense elastic fibres with collagen and surrounded by ECM.  The inner wall of 
Schlemm’s Canal was comprised of a monolayer of flat endothelial cells on a basement 
membrane.  After TGF-β2 injections, the organisation of the TM became disorganised with 
fewer trabecular cells found in an irregular array with disrupted connections with other 
trabecular cells. Homogenous granular ECM was found in the sub-endothelial region and the 
endothelium of the inner wall of Schlemm’s Canal appeared thicker (data not shown).  With 
the increase by laminin and fibronectin shown on immunohistochemistry together with the 
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ECM deposition by TEM confirm that injections of TGF-β2 caused fibrosis of the TM and 
Schlemm’s Canal. 
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Figure 4.14 TM fibrosis in the iridiocorneal angle. Parasagittal eye sections illustrating areas of fibrosis by immunostaining of (A) laminin 
(red) in the upper row and (B) fibronectin (green) with DAPI stained cell nuclei (blue) in the lower row. The circled area contains the TM. 
Immunostaining for (C) laminin and (D) fibronectin was increased in the TM after TGF-β2 injections compared to intact and PBS eyes 
(p<0.001). Scale bar – 100µm; TM – trabecular meshwork.  
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Figure 4.15 Electron micrograph of the trabecular meshwork (X2500). (A,B) In the PBS 
group, the TM showed expanded beam-like structures running in parallel and 
interconnecting with each other. In between the trabecular cells (TC), there were inter-
trabecular spaces in which there were low levels of ECM deposition.  There was a varying 
thickness of a mono-layer of endothelium on the inner wall (IW) of Schlemm’s canal (SC).  (C, 
D) In the TGF-β2 injected eyes the TM was more irregular, with disruption between TC. 
There was fewer TC and the ECM was markedly increased in the JCT region and the 
endothelium of the inner wall of SC appeared thicker after TGF-β2 compared to PBS. 
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  4.3.5.3  Bi-weekly intracameral injection of TGF-β2 decreased  
    retinal function and RGC death 
 
 
Deficits in retinal function assessment of the retina and visual pathway using flash VEP, 
occurred after bi-weekly intracameral injections of TGF-β2 on 30d (Figure 4.16). There was a 
significant decrease in theP1/N2 amplitude in the VEP recorded from TGF-β2 compared to 
PBS injected eyes (n=8; p<0.01) but there were no change in latency at P1/N2 (p>0.05).  
There were no statistical significance observed in latency or amplitude from baseline to N1 
or from N1 to P1 (data not shown).  Compared to PBS, TGF-β2 injections also decreased RGC 
numbers 30d (Figure 4.17) in retinal whole mounts by 30% with counts of 1888±100 
RGC/mm
2
 and 1316±107 RGC/mm
2 
(p<0.001), respectively.  The decrease in amplitude on 
VEP suggested that the number of axons in the visual projections was reduced which 
correlated with fewer numbers of RGC after intracameral TGF-β2 compared to PBS 
injections. Latency was unaffected, suggesting that the speed of conduction through the 
visual pathway was unaffected.  
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Figure 4.16 Functional assessment of the visual pathway using flash VEP.   
(A) Average amplitude VEP at P1/N2 after PBS and TGF-β2 injections.  There was a significant 
reduction in amplitude at P1/N2 in the TGF-β2 group compared to the PBS group (n=8 
eyes/group **P<0.01). (B) Representative VEP traces at flash intensity of 3000mcd.s/m
2
 
showing a decrease in amplitude after TGF-β2 compared to PBS injections.   
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Figure 4.17 Representative micrographs of FG
+
 RGC.  (A) FG
+
 RGC in retinal whole mounts at 
30d after bi-weekly injections of PBS (B) FG
+
 RGC at 30d after bi-weekly injections of TGF-β2. 
There were fewer RGC present after injections of TGF-β2 injections. (C) Quantification of 
FG
+
RGC survival in PBS and TGF-β2 injected eyes. Injections of TGF-β2 led to significant RGC 
death compared to PBS (n=4 eyes/group **P<0.001). Scale bar 100μm. 
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4.4 Discussion 
 
 
This study demonstrated that bi-weekly intracameral injections of both TGF-β1 and TGF-β2 
led to TM fibrosis, sustained elevations of IOP and RGC death; all pathological features of 
open angle glaucoma. Increasing levels of TGF-β1/2 in the AqH induced high levels of laminin 
and fibronectin around the TM and IOP increases, suggesting impaired AqH outflow and was 
associated with RGC loss and consequent functional deficits.  
 
 4.4.1  The effect of general compared to local anaesthetic on IOP 
 
 
It is well documented that compared to local anaesthesia IOP is lowered under inhalation 
anaesthesia in both humans and rodents (Ausinsch et al., 1975; Jia et al., 2007; Ding et al., 
2011).  In study 1 reported here, IOP in rats decreased by 22% under general anaesthesia 
compared to local anaesthesia.  IOP is the main risk factor in the development of POAG, thus 
reliable rodent models should utilise reliable and reproducible methods of recording IOP. For 
administration of local anaesthetic behavioural training was required but this proved to be 
unsuccessful and repeated handing contributed to stress the rats, resulting in more variable 
IOP readings. Other studies have successfully trained mice (Cohan et al., 2001; Jia et al., 
2011) and rats (Wang et al., 2005) to tolerate IOP measurements while awake whereas, 
varying IOP measurements have been recorded from strains making interpretation of the 
data more difficult and have recommended that IOP be recorded  under general anaesthetia 
with Isoflurane (Robertson et al., 2013).  Although Isoflurane lowers IOP, IOP tends to 
remain stable for up to 3 minutes after the induction of anaesthesia (thus providing a 
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temporal window in which to take accurate measurements) (Ding et al., 2011; Cone et al., 
2012), at which point IOP can decrease up to 20%, corresponding to the decrease in IOP 
using general anaesthesia shown in the present study.  From the results presented in this 
study (4.3.1) it was concluded that use of general anaesthesia is preferable to local 
anaesthesia to minimise distress of the rats during IOP measurements, which should be 
recorded within 3 min of induction. Thus, rats in all treatment groups were administered 
general anaesthesia.  
 
 4.4.2   Development of a sustained elevation in IOP was attained from  
   increasing AqH levels of TGF-β 
 
 
A sustained IOP elevation to  4-5mmHg above control (40%) was achieved for up to 3 weeks 
by administering TGF-β1 or 2 bi-weekly at a concentration of 5ng/µl.  In human studies IOP 
elevations of 1mmHg can significantly increase the risk of developing POAG (Coleman & 
Miglior, 2008). Thus, the modest elevation shown in this experimental model of glaucoma 
would be sufficient to replicate the modest increases in IOP recorded in patients with POAG.   
 
Consistent with other fibrotic models of raised IOP (Fleenor et al., 2006; Robertson, 2010; 
Shepard et al., 2010; Han et al., 2013; Robertson, 2013), the intracameral TGF-β delivery 
regime used here generated a sustained and significant increase in IOP by 14d compared to 
controls.  Fleenor et al., (2006) in human anterior segment perfusion studies, showed that 
TGF-β2 (at 5ng/ml) generates a steady increase in IOP (up to 13-14mmHg from control IOP 
of 8-10mmHg) to levels similar to those seen in this study.  The level of control IOP reported 
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in the Wistar rat by Robertson et al (2010) was similar of that of seen in this study 
(12mmHg), but in contrast to the results here, they demonstrated using TGF-β1 adenovirus, 
that IOP was elevated and sustained at 20mmHg from 14 - 29d after injection. However, the 
higher elevated IOP levels by increasing TGF-β1 levels, using gene-expression (Robertson et 
al., 2010), could probably be explained by the constitutive production TGF-β compared to 
the interrupted bolus regime of bi-weekly intracameral injections used in this study.    What 
hasn’t been described previously, and was shown in these studies, was that elevated IOP 
levels were maintained until the end of the experiment at 30d despite cessation of TGF-β 
injection after 16d. This demonstrates that the raised IOP in this study was not attributable 
to the continued injections of exogenous TGF-β and that the IOP elevation was a 
consequence of established outflow resistance.   
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 4.4.3   TM fibrosis resulted from increasing AqH levels of TGF-β1/2 
 
 
Using established (Botfield et al., 2014) semi-quantitative analysis these studies 
demonstrated that TGF-β1 and TGF-β2 increased ECM deposition in the TM. TM cells 
together with ECM components are required to maintain AqH outflow. Several electron 
microscopic and immunohistologic studies of glaucomatous eyes have noted excessive 
accumulation of ECM in the TM (Weinreb et al., 1996) and it is widely accepted that 
increased levels of TGF-β in the AqH in patients and rodents is associated with TM fibrosis. 
Since AqH constantly flows through the TM, its protein content, including TGF-β, directly 
alters ECM dynamics. Concentrations of TGF-β lower than those used in these studies induce 
ECM production from fibroblasts (Kottler et al., 2005). Kottler et al., (2005) observed 
increased ECM production of fibronectin and collagen induced by 0.1-5ng/ml of both TGF-β1 
and TGF-β2 in isolated human tenon’s fibroblasts.   
 
A high density of TGF-β receptors is expressed in TM cells making the TM particularly 
sensitive to the effects of raised TGF-β levels in the AqH from TM cells, the lens and ciliary 
body (Tripathi et al., 1994).  TGF-β receptor binding and subsequent intracellular SMAD 
signalling in the TM causes local fibrogenesis by increasing ECM protein translation 
(including fibronectin and laminin) and modulating ECM protease activity by down-
regulating MMPs and also up-regulating TIMPs (Weinreb et al., 1996), resulting in the 
accumulation of matrix around the TM and increased resistance to AqH outflow (Tripathi et 
al., 1994).   
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The ECM not only provides a scaffold for cells but also alters the dynamics cell-ECM 
interactions.  Laminin and fibronectin are glycoproteins that bind multiple growth factors 
and substrates and play a role in cell attachment, motility and wound healing. Laminin is 
present within the TM basement membrane and increasing levels have been noted in 
steroid induced glaucomatous cultured human TM cells (Dickerson et al., 1998). The present 
study mirrors this finding. Similarly, fibronectin, is normally localised to the trabecular beams 
and basement membranes (Weinreb et al., 1996) which is present in the TM as an insoluble 
form. The discontinuous appearance of laminin in the control eyes in this study has also 
been observed in electron microscopic studies by Gong et al. (2002). Experimental steroid-
induced glaucoma (Steely et al., 1992) and whole-eye and trabeculectomy samples (Floyd et 
al., 1985) show increased fibronectin levels in those with POAG (Babizhayev & Brodskaya, 
1989).  In addition, the electron microscopic evaluation carried out in these studies also 
illustrate the effects of excess ECM deposition in the TM as shown by the granular plaque 
appearance in and around the JCT and Schlemm’s Canal. Kottler et al., (2005) showed a 
similar granular appearance of large aggregates of activated tenon’s fibroblasts after TGF-β1 
and 2 treatment (although they stated it was more apparent after TGF-β1 compared to TGF-
β2).  Within the JCT region, cells that have adjacent basement-membrane components fill 
the spaces between ECM (Fuchshofer et al., 2006; Keller & Acott, 2013). There is also an 
array of elastic fibers which run along the endothelial inner wall of Schlemm’s Canal which 
fluctuate by mechanical stress from changes in IOP.  Studies have described the loss of TM 
elasticity in POAG and a stiffening of the JCT region, through the accumulation of cross-
linking ECM molecules (Last et al. 2011).  Giant vacuoles in the inner wall of Schlemm’s Canal 
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in POAG observed by Gong et al., (1996), were not seen in the present electron microscopic 
analysis.   
 
Interestingly, the electron microscopic analysis of the TM after TGF-β2 injections did show 
ECM accumulation in the JCT region. The JCT region is the least porous part of the TM 
containing sub-micron flow channels for AqH (Johnson, 2006) compared to the uveal and 
corneoscleral regions, which contain pore sizes of 25-75µm and 2-15µm respectively, and 
contains ECM and fibroblasts (Johnson, 2006). It is thought that the ECM in the JCT provides 
resistance to outflow (Johnson, 2006), which would support the hypothesis that IOP 
elevation is a response to the accumulation of ECM induced by exogenous TGF-β.  
 
  4.4.4  RGC death resulted from increasing AqH levels of TGF-β  
 
Elevations in IOP cause structural and functional damage to the optic nerve head leading to 
apoptotic death of RGC through many biochemical and mechanical alterations (Guo et al., 
2005; Robertson et al., 2010).  In the present study significant RGC death of 30% was 
induced by exogenous administration of TGF-β1 and TGF-β2 and these data support those 
from other TGF-β induced TM fibrotic models (Robertson et al., 2010) in which  a substantial 
loss (raw data or % loss not stated) of RGC by apoptosis was reported after increasing TGF-β 
expression in the anterior chamber.  Robertson et al., (2006) showed levels of TGF-β in the 
retina after 14d TGF-β treatment (to rule out any direct effects of TGF-β) were not increased 
compared to controls concluding that the RGC death observed was an indirect result of IOP 
elevation and not by directly attributable to RGC death from TGF-β toxicity.    Although there 
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is no precise explanation of why high IOP causes RGC death, a multitude of factors caused by 
IOP increases compression of the optic nerve head (Tsai, 2012) may contribute, including 
compromised RGC axonal transport of neurotrophic factors, activation of apoptosis and 
mitochondrial dysfunction of RGC from both biomechanical and ischemic insults. 
 
The results from this study also demonstrated differences in RGC counts related to the 
counting method used. Counts taken from a linear 250um parasagittal section of the retina 
of RGC stained with β-III tubulin and DAPI did not show any differences between TGF-β and 
control groups. However, the same treatments yielded significant results when FG
+
RGC were 
counted from whole mounted retinae.  The whole retinal counts were considered more 
suitable and reliable as the 250um linear counts may not have included the areas of cell 
death.  It is well documented that the RGC are most vulnerable to death close to the optic 
nerve head (Johnson et al., 2000; Nickells et al., 2012) and the linear counts may have 
missed these areas completely.  
 
To assess the functional integrity of the visual pathway flash VEP were recorded at 30d. Flash 
VEP has been used in other rat models of ocular hypertension to assess functional damage 
(Belforte et al., 2010).  Reduced amplitudes and increased latency occur in other 
experimental glaucoma models (Towle et al., 1983) but only a reduction in amplitude was 
observed in the present study.  A model of ocular hypertension from intracameral injections 
of chondroitin sulphate yielded differences in N2 amplitude, but not latency (Belforte et al., 
2010), as mirrored in this present study.  VEP amplitudes decrease in monkey’s with 
experimental glaucoma (Johnson et al., 1989). The VEP represents activity of all the retinal 
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and visual cortex cells and their axons so the actual location of reduced function is not easily 
identified.  
 
 4.4.5  Conclusion  
 
Taken together, these results show that raised intracameral TGF-β levels induce TM fibrosis 
and increase IOP, leading to RGC death and reduced visual function as assessed by VEP, and 
indicated that the rat TGF-β model is useful for translational studies of experimental POAG. 
Unlike the most popular experimental glaucoma models, which use artificial means (such as 
epi-scleral vein ligation or injecting micro-beads) to increase IOP, the TGF-β model is based 
on increasing IOP by inducing fibrosis of the TM as occurs in the human pathology, and is, 
therefore, suitable to assess anti-fibrotic agents as potential treatments for patients.   
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Chapter 5 
 
Decorin attenuates trabecular 
meshwork fibrosis, elevated IOP and 
RGC death  
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5.1 Rationale 
 
Current treatments for the management of POAG are based either on the chemical or 
surgical lowering of IOP with the aim of preserving retinal function (McKee et al., 2005). The 
heterogeneous and multifactorial nature of POAG poses difficulties for providing adequate 
treatments. The current treatments for IOP lowering include the use of β blockers (e.g. 
Timolol) to reduce AqH production from the ciliary body and latanoprost (e.g. Xalatan), 
which increases flow through the uveoscleral drainage pathways (Alm et al., 1995). Surgical 
options, including trabeculectomy, serve to increase AqH drainage through by-passing the 
TM.  Although helpful, these treatments do not combat the underlying fibrotic pathology 
that characterises POAG. Alternative treatment strategies that better control IOP and 
ameliorate POAG by preventing and/or reversing the fibrogenic effects of cytokines in the 
TM are needed.  
In this regard, the naturally occurring TGF-β antagonist Decorin, a small leucine rich 
proteoglycan that acts as a matrikine to directly interfere with collagen fibril assembly and 
also activate ECM-degrading proteases, thereby inhibiting fibrogenesis and inducing 
dissolution of established scar tissue (Logan et al., 1999; Davies et al., 2004; Järvinen & 
Ruoslahti, 2010; Mohan et al., 2011; Ahmed et al., 2013; Botfield et al., 2013), holds 
therapeutic promise.  
 
However, the effectiveness of Decorin for the treatment of TM fibrosis has not yet been 
elucidated. Using the developed experimental TGF-β model of TM fibrosis (Chapter 4), the 
anti-fibrogenic/fibrolytic actions of human recombinant Decorin on the TM were 
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investigated to evaluation its candidature as a therapeutic agent that attenuates established 
TM fibrosis, reduces IOP, and protects RGC from death.  
5.2  Experimental design 
  
 5.2.1 Decorin attenuates TGF-β1 induced TM fibrosis, IOP elevation and RGC death 
Intracameral injections were given bi-weekly using TGF-β10-17d then Decorin21-30d (n=3 eyes), 
regimens and tonometric IOP measurements were taken as described in Section 2.2 (Figure 
5.1). Decorin-related data were compared to that obtained in the TGF-β10-17d then PBS21-30d 
(n=6) treated rats as described in Chapter 4. All rats were killed on 30d and 
immunohistochemical analysis determined levels of laminin deposition around Schlemm’s 
canal. RGC that were βIII-tubulin
+
 were counted over a 250µm sampling line of the ganglion 
cell layer from parasagittal sections of the retina to assess RGC death.  IOP data were 
analysed for normality, followed by testing for significance (p<0.05) using generalised 
estimated equations.  The Students paired t test was used for statistical analysis of TM 
fibrosis and RGC survival. 
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Figure 5.1 Design of experiment to assess the effects of Decorin on TM fibrosis, IOP and RGC 
survival in the TGF-β1 model of induced TM fibrosis. 
 
 
 5.2.2 Effects of Decorin on TGF-β2-induced TM fibrosis, raised IOP and RGC  
  death  
Bi-weekly unilateral TGF-β20-17d then Decorin21-30d (n=12 eyes) intracameral injections were 
given and tonometric IOP measurements were taken as described in Section 2.2 (Figure 5.2). 
Decorin-related data were compared to that obtained in the TGF-β20-30d (n=12) and PBS0-30d 
(n=12) treated rats described in Chapter 4 (all in-vivo TGF-β2 studies in Chapter 4 were 
performed simultaneously to these studies). All rats were killed on 30d and electron 
microscopy and immunohistochemical analysis of laminin and fibronectin determined levels 
of ECM deposition in the angle and around the TM and Schlemm’s Canal. RGC function and 
survival were assessed using VEP and whole mounted retina retrogradely labelled with 
FluoroGold, respectively.  IOP data were analysed for normality, followed by testing for 
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significance (p<0.05) using generalised estimated equations.  The Student’s paired t test was 
used for statistical analysis of TM fibrosis and RGC survival.  Generalised estimated equations 
was used for VEP analysis and One-Way ANOVA for TM fibrosis.  
 
Figure 5.2  Experimental design to assess the effects of Decorin on TM fibrosis, raised IOP and RGC 
survival in the TGF-β2 model of induced TM fibrosis. 
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5.3 Results 
 
  5.3.1 Decorin attenuated the TGF-β induced elevation in IOP 
 
After establishing a sustained elevation in IOP using repeated intracameral TGF-β1 
injections, the administration of Decorin, from 21-30d, led to a significant decrease in IOP 
compared to eyes injected with PBS (p<0.001) (Figure 5.3). At day 21d, the IOP in the TGF-
β10-17d then PBS21-30d injected group was 14±2mmHg, which was indistinguishable from that 
in the TGF-β10-17d/Decorin21-30d group that had an IOP of 15±2mmHg. However, by 30d the 
IOPs were significantly different, so that between 21d until the end of the experiment at 30d 
the IOP in the TGF-β10-17d/Decorin21-30d group reduced from 15±2mmHg to 10±0.6mmHg, 
whereas in the TGF-β10-17d/PBS21-30d group the IOP remained elevated to 16±1mmHg.  
 
Decorin similarly attenuated the elevations in IOP induced by intracameral injections of TGF-
β2 (Figure 5.4). After 21d, TGF-β2 injections had led to a sustained elevation in IOP to 
14±0.2mmHg. When Decorin was administered between 21d to 30d (TGF-β20-17d/Decorin21-
30d group), the IOP decreased back to 10±0.3mmHg. This was significantly lower than the IOP 
of 14±0.3mmHg measured at 30d in the TGF-β2 group (p<0.001).  
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Figure 5.3 Mean IOP±SEM measurements after intracameral injections of TGF-β1±Decorin. 
The TGF-β1-induced sustained elevation in IOP was attenuated by intracameral injections of 
Decorin (TGF-β10-17d/Decorin21-30d), to levels that were significantly lower to those in the 
control group (TGF-β10-17d/PBS21-30d) (p<0.001).    
 
147 
 
 
 
Figure 5.4 Mean IOP±SEM measurements after intracameral injections of TGF-β2±Decorin. 
The TGF-β2-induced sustained elevation in IOP was attenuated by intracameral injections of 
Decorin (TGF-β20-17d/Decorin21-30d), to levels that were significantly lower to those in the 
TGF-β2 group (p<0.001).    
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 5.3.2 Decorin reversed established TM fibrosis  
 
Intracameral injections of Decorin significantly (p<0.05) reduced fibrosis (to similar levels 
observed in the PBS0-30d eyes), evidenced by more intense staining for laminin and 
fibronectin deposition around Schlemm’s Canal and throughout the TM after TGF-β10-
17d/Decorin21-30d (Figure 5.5) or TGF-β20-17d/Decorin21-30d (Figure 5.6) compared to TGF-β10-
17d/PBS21-30d and TGF-β2, respectively.  Laminin deposition after TGF-β10-17d/PBS21-30d 
injections was most prominent throughout the inner wall of Schlemm’s Canal and the JCT 
region of the TM. Collections of fibronectin deposits throughout the TM were observed after 
TGF-β10-17d/PBS21-30d  and TGF-β2  injections, however, TGF-β10-17d/Decorin21-30d and TGF-β20-
17d/Decorin21-30d were able to significantly (p<0.001) reduce these deposits, demonstrating 
lower levels of fibronectin staining to that observed in the TGF-β10-17d/PBS21-30d  and the TGF-
β2   injected eyes.    
TEM of parasagittal sections of the eyes revealed decreased ECM deposition in the angle of 
the TGF-β20-17d/Decorin21-30d injected eyes compared to that in the TGF-β2 injected eyes 
(Figure 5.7). In the JCT region of the TGF-β20-17d/Decorin21-30d eyes, ECM was absent from the 
intra-trabecular spaces and the TM was more organised than observed in the TGF-β2 
injected eyes.  The decrease in laminin and fibronectin revealed in the angle by 
immunohistochemistry, together with the appearance of less ECM deposition shown with 
electron microscopy, suggest that injections of Decorin reversed the established fibrosis 
induced by intracameral TGF-β2 injections.  
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Figure 5.5 Distribution of laminin around Schlemm’s Canal. Photomicrographs of 
parasagittal eye sections illustrating laminin staining (red) in the iridiocorneal angle (*) and 
Schlemm’s Canal. Laminin deposition was found around Schlemm’s Canal in (A) PBS0-30d, (B) 
TGF-β10-17d/PBS21-30d  and (C) TGF-β10-17d/Decorin21-30d injected eyes. Bi-weekly injections of 
Decorin between 21d and 30d (n=3) led to a significant (p<0.05) reduction in laminin 
deposition within the inner wall of Schlemm’s Canal, compared to TGF-β10-17d/PBS21-30d 
injected eyes. (D) Decorin reversed laminin deposition back to levels seen in the PBS0-30d 
group. Scale bar – 50µm; SC – Schlemm’s Canal.  
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Figure 5.6 Fibrosis in the TM. Parasagittal eye sections illustrating areas of fibrosis revealed 
by immunostaining of (A) laminin (red) and (B) fibronectin (green). The area circled in white 
defines the TM. Quantification of the immunostaining for (C) laminin and (D) fibronectin 
about the TM shows that both ECM molecules were increased after TGF-β2 injections and 
this ECM deposition was reversed in the TGF-β20-17d/Decorin21-30d injected group to similar 
levels observed in the PBS injected eyes (p<0.001). Scale bar – 100µm; TM – trabecular 
meshwork.
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Figure 5.7 TEM of the trabecular meshwork at 30d (X2500). (A) In the PBS group the TM showed expanded ‘beam-like’ ECM structures 
running in parallel and interconnecting with each other. In between the trabecular cells, the intra-trabecular spaces had low levels of 
ECM deposition (*).  There was varying thickness of a mono-layer of endothelium on the inner wall (IW) of Schlemm’s Canal (SC).  (B) In 
the TM of the TGF-β2 injected eyes the trabecular spaces were disorganised, there were fewer trabecular cells and the ECM was 
markedly increased in the JCT region and also around outer wall of SC. In addition, the endothelium of the inner wall of SC appeared 
thicker in the TGF-β2 compared to the PBS injected eyes. (C) In the TGF-β20-17d/Decorin21-30d group, Decorin had attenuated the level of 
ECM deposition in the TM compared to the TGF-β2 injected eyes, to levels seen in the PBS group.   SC – Schlemm’s Canal, IW – Inner Wall, 
ECM – Extracellular Matrix, CB – Ciliary Body. 
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 5.3.3  Decorin altered protease activity in the TM  
 
Immunostaining was undertaken to observe the localisation of injected Decorin in the TM at 
30d (Figure 5.8A).  After TGF-β20-17d/Decorin21-30d injections significant levels of 
immunoreactive human Decorin were apparent in the tissues about the TM.  Figure 5.8E 
shows quantitation of the immunostaining for human Decorin and confirms the higher levels 
of human Decorin in the TGF-β20-17d/Decorin21-30d treated eyes when compared to the PBS 
and TGF-β2 injected eyes (p<0.05). 
 
MMP2 staining was increased after TGF-β20-17d/Decorin21-30d injections to similar levels seen 
in the PBS injected eyes. There was little immunoreactive active MMP2 apparent after TGF-
β2 injections. Similarly, the TGF-β2 injected eyes had lower levels of immunoreactive active 
MMP9 than did TGF-β20-17d/Decorin21-30d and PBS injected eyes.  Conversely, TIMP2 
immunoreactivity was highest in the TGF-β2 injected eyes and was lowest in the Decorin 
treated eyes, compared to TGF-β2 and PBS treated eyes.  Quantitation of the 
immunoreactivity confirmed that TGF-β20-17d/Decorin21-30d treatment led to significant 
(p<0.05) increases in active MMP2 and MMP9, and a significant (p<0.001) decrease in active 
TIMP2 (Figure 5.8E) about the TM. These results indicate that TGF-β2 down-regulated both 
MMP2 and MMP9 bioactivity in the TM and that Decorin antagonised this effect, suggesting 
a mechanism for Decorin’s fibrolytic actions to reverse fibrosis in the TM.  
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Figure 5.8 Human Decorin and protease activity in the TM at 30d. Representative images of 
immunoreactive (green) (A) Human Decorin, (B) MMP2, (C) MMP9 and (D) TIMP2 in the PBS, 
TGF-β2 and TGF-β20-17d/Decorin21-30d injected eyes with (E) quantification of pixel intensities 
above a set threshold (* p<0.05; *** p<0.001). DAPI (blue) was used to mark cell nuclei. 
Scale bar – 50µm; TM – trabecular meshwork; CB ciliary body. White lines demarcate the TM 
in A-D. 
E 
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 5.3.4 Decorin treatment protected RGC from death but did not from functional 
  compromise 
 
Between-subject analysis showed no functional recovery of the retina or visual pathway 
after TGF-β20-17d/Decorin21-30d treatment using Flash VEP compared to TGF-β2 treatment at 
P1/N2 (Figure 5.9).    Overall, there were no significant differences between the treatment 
groups across all three flash intensities at the P1/N2 amplitude or latency (p=0.571).   Eyes 
injected with TGF-β20-17d/Decorin21-30d had a significantly higher number of surviving RGC at 
30d compared to TGF-β2 injections, with 1794±107 RGC/mm
2
 and 1316±146 RGC/mm
2
 
respectively (p<0.001). Decorin treated eyes had similar RGC counts to the PBS injected eyes 
1888±100 RGC/mm
2
 (Figure 5.10). These data suggested that Decorin was able to prevent 
further loss of RGC but was not able to restore or prevent functional deficits.  
 
 
 
 
 
 
 
 
Figure 5.9 Flash VEP summary of P1/N2 amplitude at 30d.  Decorin from day 21 to 30 did 
not have any effects on visual pathway function compared to TGF-β2 injected eyes (n=8; 
p=0.571).  
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Figure 5.10 Representative photomicrographs and quantitation of FG-labelled RGC for 
assessment of RGC survival.  (A) FG-labelled RGC at experimental day 30 after PBS 
injections; (B) FG-labelled RGC at experimental day 30 after TGF-β2injections; (C) FG-labelled 
RGC at experimental day 30 after TGF-β20-17d/Decorin21-30d injections. (D) Quantification of 
RGC survival in all three groups. Decorin21-30d treatment significantly reduced the amount of 
RGC death compared to TGF-β2 injections (n=4 eyes/group **P<0.001) and yielded similar 
counts to those in the PBS injected eyes. Scale bar = 100μm. 
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5.4 Discussion 
 
This study showed that intracameral Decorin treatment led to MMP-induced dissolution of 
established TM fibrosis with associated lowering of raised IOP and indirect protection from 
progressive RGC death.  
 
 5.4.1 Decorin reduced elevations in IOP through attenuating TM fibrosis 
 
In this study the sustained elevation of IOP, induced by TGF-β, was attenuated by Decorin. 
Sequential staging of the injections of TGF-β and Decorin excluded the possibility of direct 
interference by Decorin in the binding of exogenously delivered TGF-β to the TGF-β receptor, 
implying that the IOP reduction observed resulted from lysis of the established TM fibrosis, 
probably by activation of locally produced fibrolytic MMP.  In this study, Decorin had 
significantly reduced IOP within 72 hours suggesting a fibrolytic response had occurred 
within this timeframe and therefore reduced the IOP compared to PBS controls, which 
remained significantly higher. Similar acute fibrolytic actions of Decorin have been previously 
reported by Botfield et al. (2014) who demonstrated a reduction in fibrosis and 
inflammation within the brain after 3 days of Decorin treatment.  Decorin has also been 
reported to lower IOP by 3 days in a rabbit model of glaucoma filtration surgery (Grisanti et 
al, 2005), supporting our attribution of fibrolytic properties to Decorin in the TM.  The 
observation that Decorin promoted the dissolution of established ECM protein deposits in 
and around the TM by activating the MMP axis is supported by observations in multiple 
rodent CNS injury models that demonstrate Decorin’s anti-fibrogenic and fibrolytic actions in 
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both acute and chronic scarring situations (Logan, 1999; Davies, 2004; Ahmed et al., 2013; 
Botfield et al., 2013).    
 
The fibrolytic actions of Decorin were evidenced by monitoring the levels of laminin and 
fibronectin in the TM. Data presented in Chapter 4 showed that TGF-β induced laminin and 
fibronectin deposition in the angle and that the levels of these ECM molecules were 
attenuated by Decorin after TGF-β injections were stopped and any exogenous TGF-β would 
have cleared from the anterior chamber by this time and only endogenously released TGF-β 
would be present. Decorin’s anti-fibrotic actions, through direct inhibition of endogenous 
TGF-β, have been documented in the rat brain (Logan et al., 1999; Botfield et al., 2013) and 
other fibrotic diseases including cirrhosis (Baghy et al., 2012), lung fibrosis (Kolb et al., 2001), 
cardiac fibrosis (Yan et al., 2009) and renal fibrosis (Isaka et al., 1996). It is unclear if 
Decorin’s actions in the eye are the result of inhibiting endogenous TGF-β or achieved solely 
through TGF-β independent mechanisms. This would need to be tested in future studies, for 
example, by administering Decorin in combination with TGF-β antibodies (to neutralize 
endogenous TGF-β) to measure the TGF-β independent effects of Decorin on TM fibrosis.   
 
Notwithstanding, Decorin increased levels of MMP2 and MM9 and decreased TIMP2 in the 
TM compared to eyes that were treated with TGF-β alone. This data supports findings from 
Ahmed et al., (2013) who demonstrated the Decorin treatment after spinal cord injury 
increased MMP2 and MMP9. The rebalancing of the MMP:TIMP ratio to favour protease 
activity by Decorin shown in this study  mirrors the pathological process shown from 
patients with POAG where MMP, released from TM cells, have a role in controlling IOP 
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through regulation of ECM degradation in the TM (Schlötzer-Schrehardt et al., 2003). Eye 
perfusion studies have shown that the stretching of TM cells that occurs with increased IOP 
upregulates levels of MMP2 and downregulates levels of TIMP2 favouring ECM degradation 
in an attempt to reduce outflow resistance and lowering IOP (Bradley et al., 2003).  It is 
becoming more widely accepted that dysfunctional ECM remodelling leads to TM fibrosis in 
open angle glaucoma (Maatta et al., 2002; Yang et al., 2003; Rönkkö et al., 2007). This study 
has shown that Decorin was able to reverse established TM fibrosis and to restore 
proteolytic activity in the TM, probably in part through by modulating MMP bioactivity, 
making it ideal drug for further investigation as a therapeutic agent in POAG.  
 
 5.4.2 Decorin indirectly protected against progressive RGC Death  
 
The increased MMP activity, the reduction in TM ECM immunostaining and the lowering of 
IOP seen after Decorin treatment of established TM fibrosis was correlated with increased 
RGC survival compared to controls.  However, the RGC survival was not correlated with 
evidence of functional preservation after Decorin treatment as measured by VEP.  
 
In vitro studies from our laboratory have demonstrated that Decorin is not directly 
neuroprotective to RGC (Peter Morgan-Warren, unpublished work), providing evidence that 
the Decorin-related neuroprotection seen in this study was attributable to its IOP lowering 
effects from MMP-induced dissolution of TM fibrosis.  Although there is no precise 
explanation of why high IOP causes RGC death, a multitude of factors may contribute, 
including compromised axonal transport of neurotrophic factors, activation of apoptosis and 
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mitochondrial dysfunction of RGC from both biomechanical and ischemic insults caused by 
compression of the optic nerve head (reviewed in Almasieh et al., 2012).  
 
Given the high level of RGC survival after treatment with Decorin, it was surprising that there 
was no functional preservation measured by VEP. This result could have been attributed to 
the between, rather than within, subjects experimental design in comparing TGF-β with 
Decorin, thereby confounding the VEP data. These results could have been further 
confounded by the incomplete occlusion of the contralateral eye during recording. In future 
studies, a within subjects design for VEP studies would be more suitable as variability 
between animals will be minimised.  
 
 5.4.3  Conclusion 
 
Intracameral Decorin treatment effectively reversed established TM fibrosis and lowered 
IOP, and thereby indirectly protected RGC from progressive IOP-related death.  Thus, 
intracameral Decorin has the potential to be developed into an effective therapy for patients 
with POAG. 
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Chapter 6 
 
 
Transcorneal delivery of Decorin 
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6.1 Rationale 
 
 
The previous chapter showed that intracameral injections of Decorin that increase Decorin 
titres within the AqH were efficacious in attenuating chronic TM fibrosis.  Although bi-weekly 
intracameral injections proved to be an effective means of achieving proof of principle data 
in an experimental model of raised IOP that supported Decorin’s therapeutic potential to 
treat POAG, this delivery method would not be an ideal treatment regime for patients in 
clinic.  Therefore, a more suitable method of drug delivery would be better suited in order to 
advance these studies towards pre-clinical testing.  
 
Most patients are given drugs in the form of eye drops to manage their IOP. Therefore, 
developing a similar method to deliver Decorin would prove valuable.  Decorin is a 70kDa 
(Brandan et al., 1992) negatively charged glycoprotein, and due to its large size and charge is 
likely to be unable to penetrate and traverse epithelial barriers unaided.  We hypothesised 
that formulation of Decorin with a nanosome (NS) based carrier molecule would enable 
Decorin to successfully cross the cornea. In collaboration with Dr. de Cogan (University of 
Birmingham), an arginine rich polypeptide (NS) that can be electrostatically or covalently 
bound with Decorin was developed to assess if NS-Decorin-complexes could penetrate the 
cornea and deliver pharmacologically relevant titres of the drug into the AqH of rodents.   
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6.2  Experimental design 
 
Adult rats (n=4) had 3 drops of 60µl of the 2 NS-Decorin formulations (± electrostatic or 
covalently bound Decorin) given to each eye. All left eyes were given Nanosome-PBS drops 
and all right eyes given NS-Decorin eye drops. Four further control groups were Intact eyes 
(n=4), eyes given PBS eye drops (n=4), eyes given NS in PBS eye drops (n=4) and eyes given 
Decorin in PBS eye drops (n=4). Two minutes after the eye drops were administered, rats 
were killed using increasing concentrations of CO2 over 8 minutes to enable a 10 min timed 
experiment. Thereafter, 10µl of AqH was removed from the anterior segment of each of the 
4 eyes/group that was pooled together to give a final volume of 40μl AqH. The AqH samples 
were analysed to measure the Decorin concentrations achieved 10 min after application 
using the commercially available human Decorin ELISA kit (R&D Systems, Cat: DY143). The 
ELISA protocol was performed as directed in the kit instructions. 
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6.3 Results 
 
No human Decorin was detected in the pooled AqH samples following NS+PBS eye drops. 
Following application of the NS-Decorin covalent eye drops and the NS-Decorin electrostatic 
eye drops, 17.6ng/ml and 16.9ng/ml of human Decorin was detected in the AqH, 
respectively. This data demonstrates that Decorin successfully traversed the cornea into the 
AqH and that the covalent and electrostatic eye drops were equally effective. 
 
Figure 6.1 Levels of human Decorin±SEM in AqH after NS eye drops. Human Decorin was 
detected by ELISA in the AqH 10 minutes after covalent and electrostatic NS-Decorin eye 
drops were applied to the cornea.  
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Movement into the anterior chamber of the NS-Decorin eye drop was captured using OCT 
anterior segment imaging, whereby fluorescently labelled NS-Decorin complexes were as 
bright dots (Figure 6.2).  Immediately after the eye drops were applied they formed a 
droplet that covered the cornea (Figure 6.2 A), then at 6 minutes the labelled NS-Decorin 
complexes were seen to have penetrated through the cornea into the anterior chamber 
(Figure 6.2 B). These observations suggest that the NS-Decorin complexes had aggregated 
permitting them to be visualised (this aggregation of the complexes was later confirmed by 
Dr De Cogan using dynamic light scattering).  
 
 
 
 
 
 
Figure 6.2 OCT imaging of NS-Decorin complexes crossing into the anterior chamber using 
Fluorescein angiography (blue light, 465-490nm).  (A) Eye drops containing fluorescently 
labelled NS-Decorin complexes were placed onto the cornea. (B) After 6 minutes the 
fluorescently labelled NS-Decorin complexes had traversed the cornea into the anterior 
chamber.  
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6.4 Discussion 
 
This study showed that electrostatically and covalently bound NS-Decorin complexes when 
given in an eye drop formulation were able to traverse the cornea into the anterior 
chamber, and be detected in the AqH using OCT. As both NS-Decorin formulations were 
equally able to penetrate the cornea, the ionic formulation was chosen as more favourable 
as the peptide synthesis required less harmful chemicals that would be less likely to cause 
any ocular surface irritation.  
 
The cornea presents a significant barrier to drug permeability, especially for large molecules 
like Decorin, as its multiple layers include a lipophilic endothelium, a hydrophilic stromal 
layer, an  ECM layer and an epithelial layer.  In addition, there are  multiple phases where 
the delivered drug will be diluted before reaching its intraocular target (the TM), including 
the pre-corneal tear film and the AqH itself. The previous studies (Chapter 5) showed 
efficacy of Decorin at a dose  3µl of 5mg/ml directly injected into the anterior chamber of 
15µl which is a much higher dose that the 2ng/ml detected in the AqH after the eye drop 
delivery.  Hence, the therapeutic efficacy of the NS-Decorin eye drop formulation will have 
to be tested in further studies as it is still unclear if the final concentration achieved in the 
AqH will be sufficient to reverse TM fibrosis in experimental glaucoma. 
 
The use of arginine polypeptides have been previously reported as  useful carrier moieties to 
deliver drugs across biological barriers due to their cell penetrating properties, with 
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particular emphasis in previous studies on delivering insulin across gut epithelium (Morishita 
et al., 2007).  Of direct relevance, a recent study by Liu et al., (2014) demonstrated the use of 
polyarginines for intraocular drug delivery and the study reported herein was able to provide 
confirmatory evidence that polyarginine NS are suitable carriers for drug delivery into the 
eye. 
 
In summary, this data has given proof of principle that Decorin is able to traverse the cornea 
into the anterior chamber when joined with a known cell penetrating compound consisting 
of polyarginines. With further development, this may provide a basis for delivering Decorin 
at therapeutic titres into the anterior chamber as a treatment for experimental glaucoma. It 
also provides a translational arm that holds potential for advancing these studies with 
Decorin towards the clinic.  
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Chapter 7 
 
 
General Discussion 
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7.1  General conclusions 
 
 
The first aim of these studies was to develop a rodent model to mirror certain pathological 
aspects of POAG, namely fibrosis of the TM, elevations in IOP and RGC death. The second 
aim was to assess the potential value of intracamerally injected Decorin as a therapeutic 
agent that attenuated chronic TM fibrosis, thereby reducing IOP and limiting progressive 
RGC death. Finally, the third aim was to pilot an eye drop method of Decorin delivery to the 
anterior chamber, which could be easily adopted in a clinical setting.   
 
Two in vivo models were developed; the kaolin and the TGF-β models. Intracamerally 
injected kaolin did not induce fibrosis in the TM in these experiments, nor did it raise IOP 
(Chapter 3).  Although transient peaks in IOP were observed acutely, they were not 
sustained, even though kaolin remained present within the angle in some rats. In addition, 
there was no evidence of induced TM fibrosis, although the addition of LPS did induce an 
inflammatory response in the anterior chamber with a noticeable increase in the numbers of 
ED1+ macrophages present. Therefore, the kaolin model was deemed unsuitable to model 
chronic TM fibrosis and IOP elevation although, when given in combination with LPS, it might 
be a useful model for anterior segment inflammation.   
 
TGF-β was predicted to be a more appropriate agent to induce chronic TM fibrosis since it is 
widely accepted that active TGF-β levels are higher in the AqH of patients that develop 
POAG.  Initially a dosing regimen was piloted along with investigation of IOP variability using 
local or general anaesthetic for the surgical procedures. Other research groups differ in their 
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preference for anaesthesia of rodents in their experimental models. The most notable 
reason for using local anaesthetic is to avoid the associated lowering of IOP, however, the 
results of these studies and others (Robertson et al., 2013) deemed the use of general 
anaesthetic in rodents as providing a more reliable measure of IOP. General anaesthetics 
minimise having to train rodents and avoids any compromising distress of the animals. Any 
confounding lowering of IOP between treatments was avoided experimentally, as both 
treatment and controls injections were administered under general anaesthesia would 
receive the general anaesthesia, thus reducing any bias in results due to variable 
anaesthesia. The other reason to choose general anaesthetic over local, was the unfeasibility 
of performing intraocular injections on awake rats.  In addition, IOP were generally taken 
just before rats were given intracameral injections, which was required by our home office 
license to be carried out under general anaesthetic.  Thus, using a general anaesthetic 
helped to streamline the surgical procedures, thus making it less stressful for the animals 
and providing a more controlled experiment.  
 
The initial TGF-β studies were conducted using TGF-β1. However, two weeks of bi-weekly 
intracameral injections of either active TGF-β1 or TGF-β2, achieved similar sustained 
elevations in IOP of 30-40%, associated with significant TM fibrosis and 30% RGC death by 30 
days. It is generally accepted that TGF-β2 levels are higher in patients with POAG (Inatani et 
al., 2001), whereas higher levels of TGF-β1 are mostly associated with the development of 
PXG.  Experimental models using Tenon’s capsule fibroblasts from patients to assess 
fibrogenic effects of both TGF-β1 and 2 also noted non-significant differences between the 
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levels of TGF-β isoforms in terms of the type and morphology of ECM deposition and fibrosis 
with higher TGF-β2 levels being associated with enhanced fibrosis (Kottler et al., 2005).  
 
Accordingly, although the differences between TGF-β1 and TGF-β2 were not thoroughly 
investigated in this thesis (EM nor VEP were assessed after TGF-β1 injections, but were after 
TGF-β2), it was decided after the initial TGF-β1 studies that TGF-β2 would be the more 
appropriate isoform to use for subsequent studies.  
 
The studies reported here highlighted several technical issues that were addressed by 
modified experimental design. For example, levels of ECM deposition were measured using 
changes in pixel intensities; this is a subjective semi-quantitative method. Using western blot 
or ELISA to objectively measure ECM deposition from protein levels would be preferable in 
future studies. Another issue was related to the method of counting RGC.  There was a 
difference between the RGC counts obtained from β-III tubulin stained parasagittal sections 
and those from whole mounted retinae after retrograde FluoroGold labelling so that, after 
raised IOP, RGC death was recorded at 8% and 30% respectively.  The retinal whole mount 
method was used in subsequent studies as it was felt to be more representative, with 
FluoroGold-labelled RGC counts being sampled across the whole retina. FluoroGold is a more 
specific marker of RGC than β-III tubulin, which relies heavily on the experimenter to identify 
immunopositive RGC within retinal sections based on location and morphology.   Another 
technical issue of note was the observation that in the TGF-β2 model of raised IOP, it was 
possible to demonstrate a functional deficit on VEP with lower amplitudes, which provided 
evidence of the visual pathway being disrupted. This feature was reminiscent of 
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observations in patients with POAG although, unlike in POAG patients, there were no 
alterations in latency (Parisi, 2001). 
 
The TGF-β2 model was thus employed to investigate the potential use of recombinant 
human Decorin to target and reduce established TM fibrosis (Chapter 5).  Decorin had 
already shown much potential to reverse fibrosis in other rodent models (Botfield et al., 
2013, Ahmed et al., 2013), therefore it was ideally suited to be tested in this new 
experimental model of POAG, which is based around the induction of chronic TM fibrosis. A 
GCP grade of Decorin was used in these studies, which is helpful as the same molecule can 
be carried through from pre-clinical to clinical studies in patients.  
 
The studies described showed that Decorin was able to reverse established fibrosis in the 
TM, leading to lowering of IOP, thereby indirectly protecting RGC from progressive death.  
Through analysis of MMP and TIMP immunostaining it was determined that Decorin 
(Chapter 5) was able to reverse established TM fibrosis through altering ECM turnover, 
providing a fibrolytic microenvironment rather than the pro-fibrogenic microenvironment 
induced through exogenous administration of TGF-β2 (Chapter 4).  Although treatment with 
Decorin was able to reverse established TM fibrosis, lower IOP and indirectly protect RGC, it 
did not provide any functional benefit according to the VEP data. It is thought that the 
between, rather than within, subjects design had confounded the data recorded here so the 
experimental design would need to be altered to record a within subjects VEP, as was 
carried out in the TGF-β2 alone studies.  Another limitation presented in these studies was 
not recording ERG during the functional testing experiments. It was thought that VEP was 
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the most suited method to validate the TGF-β model as there were functional deficits shown 
on VEP demonstrating a reduced visual pathway function to the brain. However, ERG would 
have been more sensitive to pick up death of cells within the retina and may have been 
more suited to highlight any functional alterations from cell survival within the retina after 
Decorin treatment.  
 
Finally, after showing promise as a fibrolytic agent that attenuated established TM fibrosis, a 
novel method of transcorneal Decorin delivery was developed and tested in vivo. The use of 
a polypeptide arginine conjugated with Decorin showed that the proteoglycan could cross 
the cornea and penetrate the anterior chamber suggesting that this drug formulation could 
be further developed as a non-invasive method of drug delivery that could be carried 
forward for next phase pre-clinical and clinical studies.  
 
7.2  Limitations and future studies 
 
 
 7.2.1 Alternative method for IOP monitoring 
 
All the IOP monitoring carried out in these studies was intermittent and could, therefore, 
only provide snapshot IOP values. Although all experiments were designed to take the IOP at 
the same time of day and at the same frequency for both controls and treatment groups, it 
may be more useful to conduct continuous IOP monitoring using a contact lens sensor as has 
been trialled in patients (Mansouri et al., 2012) or pressure sensors as used in rabbits 
(McLaren et al., 1996).  Continuous monitoring of IOP would provide valuable data on IOP 
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variations throughout a 24 hour time period, permitting any spikes or dips in IOP to be 
observed, which were not apparent in these studies.  
 
 7.2.2 Use of contralateral eye for controls 
One limitation of this study was the use of the contralateral eye for control PBS injections.  
Rodent studies have demonstrated that raised IOP in one eye caused microglial activation in 
the untreated, normotensive,  contralateral eye (Rojas et al., 2014).  Systemic absorption of 
agents into the anterior chamber may also alter the IOP in contralateral eyes (Urtti & 
Salminen, 1993).    However, the control data presented here were significantly different to 
that in the treatment data sets obtained from the same rat using contralateral eyes for 
controls. This demonstrated that any IOP altering effects to control eyes contralateral to 
treatment eyes were negligible.  Had the control (PBS) group IOP data been similar to the 
test (TGF-β / Decorin) groups, the systemic effects of TGF-β and Decorin would have been 
investigated further.    
 
The use of the contralateral eye for a control is a well-established method in other ocular 
hypertensive models (Ueda et al., 1998; Moreno et al., 2005; Urcola et al., 2006) and this 
experimental design was therefore deemed appropriate for the IOP models presented here. 
In addition, the use of a contralateral eye as a control enables a reduction in the number of 
animals used.  
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 7.2.3 Longer experimental time points  
 
Longer term studies would be useful to ascertain if the TGF-β2-induced rise in IOP was 
sustained over many weeks or months as shown in other experimental glaucoma models. In 
these studies, the main experiments were all conducted over a 30 day time period. This was 
decided based on the time taken to induce a sustained elevation in IOP in pilot studies (2 
weeks) and the time that it took for IOP to be brought back to baseline after Decorin pilot 
studies (4 weeks).  It is not clear from these studies what would have happened after 4 
weeks. Chapter 5 has shown evidence of Decorin reversing established fibrosis, so future 
studies should involve longer time course experiments which cease Decorin treatment after 
weeks 2-4 and monitor IOP for a further few weeks to see if it remains at normal levels, as 
would be expected to happen if TM fibrosis had been reversed. 
 
 7.2.4 The TGF-β model versus alternative models of TM fibrosis to   
  assess  the effects of Decorin 
 
Decorin is a direct antagonist for TGF-β, therefore inducing TM fibrosis using exogenous TGF-
β could be considered to be a confounded factor in this experimental model. However, the 
experiments were designed with sequential staging and temporal spacing of the injections of 
TGF-β and Decorin to overcome any direct interference by Decorin in the binding of 
exogenously delivered TGF-β. Hence, this implied that the IOP reduction observed with 
Decorin treatment resulted from lysis of the established TM fibrosis probably by activation 
of locally produced fibrolytic MMP.   Ideally, Decorin will need to be tested in another model 
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of TM fibrosis which is induced in a TGF-β independent manner. It is possible that TM 
fibrosis could be induced through administration of steroids, which are known to increase 
the risk of developing POAG in a subset of patients through increasing myocilin expression in 
the TM, thus reducing outflow and increasing IOP (Jacobson et al., 2001). Accordingly, 
Decorin could be tested in a steroid-induced model of TM fibrosis in future work.   
 
Another fruitful avenue of investigation would be to assess the levels of fibrosis attained 
after 2 weeks, the point at which raised IOP was deemed to be sustained, so that TGF-β2 
injections ceased before administering Decorin.  However, we tried to address this through 
the switching of TGF-β to PBS (Chapter 4) injections in control groups, where IOP continued 
to remain elevated compared to controls. In addition, confirming the baseline level of TGF-β 
in the normotensive rat eye may have been useful data to gather before commencing TGF-β 
injections. This would provide further information for dose/response studies with regards 
how much TGF-β would be required to more closely model in the rat what level of TGF-β 
changes occur in patients with POAG.       
   
 7.2.5 Decorin studies 
 
The Decorin studies (Chapter 5) were successful in demonstrating a fibrolytic effect in the 
TM, with lowering of IOP and subsequent protection of RGC from progressive death. 
However, the dose of Decorin used in these experiments of 5mg/ml (which would have been 
further diluted in AqH after injection) was based on previous experiments with Decorin in 
our laboratory (Botfield et al., 2013; Ahmed et al., 2013) and no dose response studies were 
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performed to ascertain the lowest concentration to show efficacy. In addition, the effects of 
intracameral injections of Decorin on normal IOP would need to be assessed as it is unknown 
from these studies if Decorin would lower IOP in normal, healthy eyes. These will need to be 
addressed in future studies.    
 
 7.2.6 Mechanisms of RGC death 
 
Another area which was not addressed in this thesis was the mechanism of RGC death that 
occurred in the TGF-β model. Some early experimental concerns that were addressed were 
the possible direct effect of TGF-β on RGC. However, others have shown that TGF-β is 
neuroprotective for cultured RGC (Walsh et al., 2011), therefore it seems most likely that the 
RGC death shown in vivo in the present studies when TGF-β2 was administered was indeed a 
result of the TM fibrosis and IOP elevation.  
 
 7.2.7 Overcoming the translational barriers in glaucoma treatment 
 
IOP lowering agents have been a success story in effective translation from animal models to 
humans, for example, the trials of Timolol in rabbit (Vareilles et al., 1977).  However, most 
neuroprotective drugs that have worked well in animal models have failed to translate to the 
clinic, mostly because of fundamental differences in ocular anatomy and relevant 
experimental designs (reviewed in Ergorul & Levin, 2013).  In order to translate Decorin into 
the clinic as a routine treatment to combat TM fibrosis it would need to be shown to be 
efficacious in a number of distinct animal models (from mouse to non-human primates) and 
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future animal model studies for experimental glaucoma should be designed as close to 
human studies as possible with regards to experimental methods, measured end points and 
disease relevant time points.  The most important barrier to translating new treatments for 
POAG into the clinic is that no single animal model can replicate the complex pathobiology 
involved in the development and progression of POAG in patients. However, animals can be 
useful in mirroring certain aspects of the disease, such as TM fibrosis, to assess the potential 
of newer treatments, including Decorin.  
 
7.3 Final conclusions 
 
Increasing TGF-β levels in AqH induced TM fibrosis, IOP elevations and RGC death, all 
characteristics of POAG. Decorin was successfully able to reduce established fibrosis, lower 
IOP and thereby, protect RGC from death. Having established Decorin’s promise as a 
fibrolytic agent to reduce established TM fibrosis, a patented method of transcorneal 
Decorin delivery was developed and, demonstrated successfully that Decorin could traverse 
the cornea and penetrate into the anterior chamber. Transcorneal Decorin delivery will be 
further developed as a non-invasive drug delivery system that could be carried forward for 
next phase pre-clinical and clinical studies.  
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